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Abstract

SYNTHESIS AND BIOCHEMICAL STUDIES ON SULFATED MONOMERS OF LOW
MOLECULAR WEIGHT LIGNINS
By Jenson Verghese, M.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Pharmaceutical Sciences at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Umesh R. Desai
Professor, Department of Medicinal Chemistry

Anticoagulants are used as the first line therapy for management and prevention of
thrombotic disorders. Thrombin and factor Xa have been the prime targets for regulation of
the coagulation cascade.
In this work, a small library of 17 benzofuran derivatives were synthesized and screened
against thrombin and factor Xa. The derivatives that displayed inhibitory potential were
docked on the exosite-II of factor Xa using a docking protocol that was developed in our
research group. These compounds were based on the β-5 structural unit found in the
oligomer ‗CDSO3‘, which was prepared in our lab and was found to inhibit both thrombin
and factor Xa by an exosite-II mediated allosteric disruption of the catalytic triad.
xii

The results revealed that these β-5 like derivatives are inhibitory against thrombin and
factor Xa, although their potency is weak. Thrombin and factor Xa appear to recognize
different structural features suggesting a significant selectivity in recognition. Furthermore,
a slight preference for the benzofuran scaffold was observed with factor Xa. Probing the
mechanism of inhibition using Michaelis-Menten kinetics reveal that these compounds
display uncompetitive inhibition of these proteases and the mechanism of inhibition is
allosteric.
Docking of these compounds on factor Xa were done using GOLD (Genetic algorithm for
ligand docking) and the results, explain the observed inhibition profile. The computed
docked poses also give an idea of the residues on the exosite-II of factor Xa critical for
inhibition.
The molecules studied here are radically different in terms of structure and mechanism of
inhibition from any other ligand described in literature. This represents an opportunity to
discover novel molecules with a possibly different pharmacological and toxicological
profile.

xiii

Chapter 1 Introduction

1.1

The cell based model of coagulation

Blood coagulation is a self defense system preventing excess loss of blood and
infiltration of microbes following injury. The initial model of the coagulation cascade
was proposed in 19601, 2 and recently a cell based model was proposed. The cell based
coagulation cascade is proposed to occur by three steps – initiation, amplification and
propagation3-5(Figure 1).
Cell surfaces localize the activation of coagulant factors, so that systemic activation of
the factors is prevented. Exposure of the transmembrane tissue factor (TF) is how
coagulation is initiated in vivo in response to a vascular injury6. The exposed TF binds to
factor VIIa to form the extrinsic tenase complex, which activates factor X and factor IX 7.
Activated factor X (fXa) activates factor V (fVa) and converts sufficient amounts of
prothrombin to thrombin to amplify the cascade and move the site of action from TF
bearing cells to platelet surfaces8. On the platelet surface fIXa binds to fVIIIa to form the
intrinsic tenase complex which activates fX, which binds to fVa and forms the
prothrombinase complex. This complex efficiently converts prothrombin to thrombin.
Thrombin converts fibrinogen to fibrin monomers and activates fXIIIa which cross links
the fibrin monomers and stabilizes the clot9.
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Figure 1

The coagulation cascade. The endogenous regulators of the cascade

include antithrombin (AT), tissue factor pathway inhibitor (TFPI) and activated protein C
(APC). HMWK: high molecular weight kininogen, TM: thrombomodulin, TM:IIa:
thrombomodulin-thrombin complex, TF: tissue factor, PL: phospholipid, F: fibrin, Fm:
fibrin monomers. (Figure was adapted from Henry, B. L.; Desai, U. R. Recent research
developments in the direct inhibition of coagulation proteinases--inhibitors of the
initiation phase. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 323-336).

2

1.2

Regulation of coagulation

Several endogenous proteins regulate the procoagulant response and prevent hyper–
coagulation by inhibiting the cascade at multiple points.
TFPI has a role in modulating the formation of the extrinsic tenase complex10. First TFPI
binds to fXa forming TFPI/fXa complex. This complex binds to fVIIa in the TF/VIIa
complex thereby regulating its catalytic activity. Also TFPI potentiates the activity of
heparins.
Activated protein C (APC); in the protein C pathway, thrombin binds to
thrombomodulin, a receptor in the endothelium12. On binding, thrombin activates protein
C which inactivates fVa and fVIIa.
Antithrombin (AT) regulates thrombin, fIXa, fXa and also TF/VIIa complex11. Heparin
induces a massive 300 – 4000 fold increase in the rate of inhibition of the target proteases
by AT.

1.3

Thrombin and Factor Xa

Thrombin and factor Xa are the most important proteases in the coagulation cascade.
Both the pharmaceutical industry and academia are actively involved in the design and
development of molecules which target either one of these two proteases. The X-ray
crystal structure of these proteases provides a useful starting point for rational design of
their inhibitors.
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Figure 2A

The topology of Thrombin. All the important domains are highlighted.

(Figure was made in SYBYL 8.1 from the protein structure 1XMN)

Figure 2B

The topology of fXa. (Figure was made in SYBYL 8.1 from the protein

structure 1HCG)
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1.3.1 The structure of Thrombin
Thrombin is a serine protease which is similar to trypsin and chymotrypsin. It has 2
polypeptide chains; A (36 residues) and B (259 residues) linked by disulfide bridges
(Figure 2A). Physiologically it cleaves fibrinogen to fibrinopeptides A and B which are
cross linked by fXIIIa to form clot. A large number of structures of thrombin have been
deposited in the protein data bank146. The enzyme is organized around 2 adjacent βbarrels in chain B and the active site residues Ser195, His57and Asp102 (chymotrypsinogen
numbering) is located between them. The active site is surrounded by the 60 and the γloops that restrict accessibility to the active site nucleophile14-17. The nomenclature given
by Schechter and Berger has been used in literature18. Here substrate residues are termed
P (for peptide) and the residues of the interacting proteases are called S (for subsite).
Substrate residues that extend toward the N terminus of the scissile bond are numbered
P2, P3… and substrate residues which extend toward the C terminus are termed P2‘, P3‘
…(Figure 3)

Figure 3

Schechter and Berger nomenclature for naming subsites (S) on a

protease and positions (P) on a polypeptide substrate.

N-terminus

Cleavage point

C-terminus

P3

P2

P1

P1'

P2'

P3'

S3

S2

S1

S1 '

S2 '

S3 '
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substrate peptide
enzyme subsites

The subsites and interacting domains present in thrombin are
The S1 site has Asp189, which is present in the bottom that recognizes
substrates/inhibitors with a basic P1 group. Also the Ser195, His57, Asp102 catalytic triad
and an oxyanion hole are present. The active site is buried inside a canyon due to the
presence of 60 and γ-insertion loops that are not present in chymotrypsinogen.
The S2 site has the residues Tyr60A and Trp60D that create the S2 pocket which
recognizes lipophillic P2 groups. Proline binds better in the S2 pocket.
The S3 site is created by the side chains of Leu99, Ile174 and Trp215. It interacts with the
hydrophobic group P3 and is more acidic when compared to other serine proteases due to
a Glu at 192.
The S4 site aliphatic residues show a preference for the S4 pocket.
The S1’, S2’ and S3’ sites recognize hydrophobic residues P1‘, P2‘, P3‘.
60 and the γ-insertion loop; the active site is buried in a narrow cleft made of the 60 and
the γ-insertion loop. The residues which make the 60 loop are more hydrophobic,
whereas the γ-insertion loop is hydrophilic and flexible. These both loops play a major
role in substrate specificity.
Two basic domains are present approximately 10-20Å away from the active site on
opposite ends. The first one located to the east of the active site is Exosite-I, which
consists of residues Lys21, Arg62, Arg68, Arg70, Tyr71, Arg73, Lys106 and Lys107. This site is
involved in the binding of fibrinogen, fibrin and coagulation factors V, VIII and XIII and
interacts with residues which are toward the N terminus of the substrate. The positive

6

field created by this site provides electrostatic steering and pre-orientation for
substrates19.
The Exosite-II is located towards the west of the active site and is the more
electropositive region19. Acidic molecules like glycosaminoglycans bind to this site and
the primary residues present in this site are His91, Arg93, Arg101, Arg126, Arg165, Lys236 and
Lys240(Figure 4A). These residues play a crucial role in interaction of thrombin with
heparin. Also not every residue present in the exosite are significant for any interactions
that occur on the site.
Thrombin utilizes both exosite-I and II for molecular recognition21,22. Anionic molecules
bind to either of the sites exclusively. The specificity of these molecules towards exosites
depend on their ionic charge. For exosite-I, hydrophobic contacts provide most of the
binding energy and electrostatics are involved in orienting the complementary
hydrophobic surfaces. Example: Hirudin which is an exosite-I ligand for thrombin, 20%
of the binding energy originates from ionic interactions23-26, whereas exosite-II
interactions are primarily ionic in nature. Example: for heparin-thrombin interactions,
80% of the binding energy is ionic27. It has been reported that both the exosites modulate
the binding of each other based on changes of fluorescence of fluorescein-FPR-thrombin
on binding with peptides28 but, Bock et al. have reported no change in KD values upon
binding of these peptides29.
The binding of ligands to both of the exosites induces conformational changes in the
active site30,

31

. This changes the specificity and reactivity of thrombin towards

macromolecular substrates. Exosite-I ligands influence the catalytic efficiency (kCAT/KM)
7

of thrombin towards hydrolysis of peptide substrates31-33, whereas exosite-II ligands like
GAG‘s have no influence on the catalytic efficiency of peptide hydrolysis 34, 35. However,
allosteric modulation of the catalytic triad through exosite-II has been observed by
chemo-enzymatically prepared lignin derivatives36, 37.
Sodium binding site; The Na+ binding site is located to the center of the 222 loop, which
is situated behind the S1 specificity pocket near Asp189. The Na+ ion is coordinated
octahedrally by carbonyl oxygens or Arg221A and Lys224 and by four internal water
molecules. This is further stabilized by the negative charges Asp221 and Asp222. Sodium is
an important allosteric modulator of α-thrombin. Two allosteric states have been
characterized kinetically in absence and presence of the Na+ ion – the slow and the fast
form. The fast form displays procoagulant, prothrombotic and prosignalling properties
whereas the slow form exhibits more anticoagulant properties38-40.
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Figure 4A

Exosite-II of thrombin (Figure was created in SYBYL 8.1 from protein

structure 1XMN)

Figure 4B

Exosite-II of fXa (Figure was created in SYBYL 8.1 from protein

structure 1HCG)
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1.3.2 The structure of Factor Xa
Factor Xa is structurally similar to the other trypsin like serine proteases in the
coagulation cascade. It is a Vitamin K–dependent glycoprotein that is synthesized from
the liver and is secreted into the blood as a zymogen97. The mature circulating form of
factor X has a light chain (139 residues) and a heavy chain (303 residues) held together
by a single disulfide bond. For activation a specific argininyl – isoleucyl (Arg52-Ile53) is
cleaved in the N-terminal of the heavy chain resulting in fXa (390 residues). The new Nterminal Ile folds into the interior of the protein and forms ion pair with an Asp residue
near the active site Ser195(Figure 2B).

The first structure of fXa determined by X-ray

crystallography was in 1990 (PDB code 1HCG)98.
The various functional domains in fXa are:
Active site S1; where the heavy chain has the residues of the catalytic triad: Ser195, His57,
Asp102 (chymotrypsinogen numbering). The overall folding resembles thrombin. The
absence of the thrombin Tyr60A – Thr60I insertion loop makes the catalytic triad more
accessible to substrates and inhibitors. Therefore the active cleft is described as more
open and groove–like, when compared to the canyon–like cleft in thrombin. An Asp189 is
present in the base of the S1 pocket which recognizes Arg like residues in the P1 site of
substrates and inhibitors. A hydrophobic ―disulfide pocket‖ is found adjacent to S1
formed by Gln192, Cys191, Cys220 and Gly218. This has been otherwise termed as the ―ester
pocket‖ due to accommodation of such groups in co – crystallization experiments99100.
S2 subsite; here a Tyr99 side chain obstructs the S2 pocket in fXa and thereby only small
aliphatic residues like glycine can interact.
10

S3 subsite; here an amide group of the conserved Gly216 can provide hydrogen–bonding
interactions with the P3 part of a substrate/inhibitor.
S4 subsite, where the residues Tyr99, Trp215 and Phe174 form an aromatic box that serves
as the S4 subsite. Moreover, the carbonyl groups of Lys96, Glu97 and Thr98 form a cation
hole at the back of the aromatic box. Aromatic interactions in the S4 pocket are crucial
for the design of inhibitors that are selective to fXa over thrombin.
Exosite-1 is the region in fXa that corresponds to the fibrinogen recognition exosite in
thrombin encompasses Asn35-Phe41 and Asp70-Ala81. Whereas this region in thrombin is
decorated with basic residues, in fXa has eight acidic groups with only one Ala. This
region in fXa is crucial for prothrombin recognition and does not recognize fibrinogen or
other exosite-I inhibitors of thrombin101.
Exosite-II; Of the eleven basic residues seen in the exosite-II in thrombin, seven are
found to be conserved in fXa. These residues are Arg93, Lys96, Arg125, Arg165, Lys169,
Lys236 and Arg240 (chymotrypsinogen numbering). This region is otherwise called as the
―Heparin binding Exosite‖. This region is found towards the west of the active site on
exposed surface loops (Figure 4B). Full length high affinity heparin can interact with this
site to produce ~200-300 fold greater acceleration of the reaction with antithrombin.
Additionally, residues in this site have been implicated in binding of fXa with fVa and
formation of the prothrombinase complex101,102.
Ca2+ binding site; fXa has a three Ca2+ binding sites. There is one on the N-terminus Gla
domain which is required for binding to fVa in the prothrombinase complex. The other

11

two sites are on the epidermal growth factor – like domain (EGF-1) and the C-terminal
catalytic domain, which includes conserved loop spanning residues 70 – 80103-105.
Na+ binding site; the 225 loop in fXa has been identified as the sodium binding site
which is similar to thrombin. Studies in which the residue Tyr225→Pro, displayed that
specific binding of Na+ to this loop increases the catalytic activity of fXa towards small
synthetic substrates and antithrombin106,107.
Furthermore, it has been shown that there exists an allosteric linkage between the Na+
binding loop and the Ca2+ binding (Glu70-Glu80) that modulates the structure and function
of fXa108.

1.4

Rationale for inhibition of thrombin and fXa

Thrombin is the final serine protease involved in the coagulation cascade. It converts
fibrinogen to fibrin and activates factor XIII which cross links the fibrin monomers.
Thrombin amplifies its own generation by activation of factor VIII and factor V which
are cofactors for the intrinsic tenase and prothrombinase complex and also by indirectly
activating factor IX - the enzyme constituent of the intrinsic tenase. Additionally
thrombin acts as a potent platelet agonist. By recruiting platelets to the site of vascular
injury, these activated platelets further add to thrombin generation. With this significant
role in thrombosis and hemostasis, thrombin is a major point for inhibition in the cascade
(Figure 5). Moreover, data from clinical trials with direct thrombin inhibitors indicate
that short term and long term inhibition of thrombin is both safe and effective41, 42.
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Factor X can be activated by the contact pathway or by the tissue factor/VIIa pathway.
Thereby initiation of coagulation by either pathway in response to any vascular injury
activates factor X to fXa. So, pharmaceutically it is a desired intervention point in the
development of anticoagulants109. The activated factor X with its cofactor fVa combine
on anionic surfaces (phospholipid membranes) to form the prothrombinase complex
which converts prothrombin to thrombin.
Factor X deficiency manifests as severe bleeding diatheses. Patients display very low
antigen and activity levels of fXa. A number of variants of fXa deficiency suggested that
factor X activity levels must be less than 5% of normal to display bleeding tendencies110112

. This proved that activity of factor X can be suppressed distinctly without affecting

hemostasis. Thus an ideal anticoagulant could stop thrombosis without causing systemic
hypocoagulation.
Studies carried out by Eisenberg et al. showed that fXa in thrombi is enzymatically active
and was able to convert prothrombin to thrombin113-114. Also, fXa is accountable more
than thrombin for clot associated procoagulant activity. The procoagulant activity of
thrombi is due to the de novo conversion of prothrombin to thrombin and not due to
circulating thrombin. These data suggest that in thrombi fXa is active and direct
inhibition of thrombus associated fXa would be an effective approach to prevention of
thrombus growth115.

13

Figure 5

A simplified scheme of the coagulation cascade. The intervention point

for fXa and fIIa inhibitors is shown (Figure was adapted from Leadley, R. J.,Jr
Coagulation factor Xa inhibition: biological background and rationale. Curr. Top. Med.
Chem. 2001, 1, 151-159).
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1.5

Inhibitors of Thrombin

1.5.1 Indirect inhibitors
These molecules exploit an intermediate physiological protein to inhibit the procoagulant
protease.
1.5.1.1 Heparin and its derivatives
Unfractionated heparin (UFH) is an acidic linear polysaccharide composed of alternating
1-4 linked uronic acid and glucosamine residues (Figure 6). It has a MW of ~15000 Da.
Low molecular weight heparins (LMWH) are produced or fractionated from UFH by
chemical or enzymatic depolymerization techniques43. They usually retain a structure
similar to UFH although the different methods used in their preparation increase their
structural heterogeneity. UFH is the strongest acid in human physiology due to the
presence of numerous sulfates and carboxylates that span the saccharide chain (~3.7
negative charges per disaccharide). The pentasaccharide sequence, which is composed of
5 residues DEFGH, mediates the interaction with antithrombin (Figure 7). Antithrombin
(AT), a serine protease inhibitor (SERPIN), is a plasma glycoprotein which inhibits its
target proteases by a serpin mouse trap mechanism. It uses its P1-P1‘ residues in its
reactive center loop (RCL) to bind to the target serine protease. After binding of the
protease to the RCL of AT to form a Michaelis - Menten complex (E:AT), the scissile
bond P1-P1‘ is cleaved to form an acyl-enzyme intermediate(E-AT), which rearranges to
disrupt the catalytic triad of the enzyme (E*-AT*). A competing pathway called the
substrate pathway may operate in parallel where in mutational changes in AT may cause
hydrolysis of the acyl – enzyme intermediate (E-AT) to yield an active enzyme (E) and a
15

cleaved inhibitor (ATC) (Figure 8). The target proteases for AT are fIIa, fXa, fIXa. In
presence of heparin, the inhibition rate constants of AT for these proteases increase 102106 fold11, 44.
AT inhibits the procoagulant proteases by two separate mechanisms. The first one is the
allosteric activation of AT by the sequence DEFGH. After recognition of the
pentasaccharide sequence by AT, a change in conformation of the partially inserted RCL
occurs11,45,46. This induces an accelerated cleavage of the RCL and explains the rate
acceleration of fXa inhibition by ~300 fold in absence of Ca2+.
Inhibition of thrombin by AT in presence of UFH is by the bridging mechanism. Binding
of AT to the UFH chain is followed by thrombin binding at non-specific positions along
the polysaccharide chain. Thrombin then diffuses along the chain to form the Michealis Menten complex (E:AT), resulting in a 102-106 fold increase in the inhibition rate
constants27 (Figure 9). LMWH and the pentasaccharide sequence by itself cannot inhibit
thrombin as the minimum chain length of ~18 residues is required for the bridging
mechanism44, 47.
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Figure 6

General structure of heparin (Figure adapted from Henry, B. L.; Desai,

U. R. Recent research developments in the direct inhibition of coagulation proteinases-inhibitors of the initiation phase. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 323336).

Figure 7

The pentasaccharide binding sequence.
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Figure 8

A model of the antithrombin inhibition mechanism (Figure is adapted

from Desai, U. R. New antithrombin-based anticoagulants. Med. Res. Rev. 2004, 24, 151181).
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Figure 9

The mechanism of how procoagulant proteases are inhibited by full

length heparin (Figure is adapted from Desai, U. R. New antithrombin-based
anticoagulants. Med. Res. Rev. 2004, 24, 151-181).
.

1.5.1.2 Warfarin
Warfarin is an indirect oral anticoagulant that inhibits vitamin K dependent post
translational modification of glutamic acid to γ-carboxyl glutamic acid, which are present
on the N terminus of Vitamin K dependant proteins eg: factor II, VII, IX and protein C, S
and Z48 (Figure 10).
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Figure 10

The structure of warfarin.
O

O

OH

Warfarin
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1.5.1.3 Limitations of indirect anticoagulants
All anticoagulants pose an excessive risk for bleeding. UFH can cause heparin-induced
thrombocytopenia (HIT), which is a significant drop in platelet count that happens
between 4-14 days of therapy49. HIT has been classified into two; Type 1 and Type II.
The type II HIT is the most severe and is characterized by the development of antibodies
against heparin-platelet factor 4 (PF4) complex50. Platelet factor 4 is a protein found on
platelets and interacts with heparin to from a tetrameric complex. Once the heparin-PF4
complex is formed it is recognized by antibodies on the platelet surface. In due course,
these platelets form a thrombus effectively being removed from circulation51. Usually,
the majority of HIT episodes occur with UFH, although cases with LMWH are also
reported52.

Additionally, UFH displays significant intra- and inter-patient dose

variability. Moreover, heparins do not neutralize clot bound thrombin, which increases
the possibility of reactivating clotting at a later time53, 54.
In 2007-2008, reports of serious allergy and hypersensitivity-type reactions surfaced
following the use of UFH resulting in at least 81 cases of death. Investigations revealed
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that the UFH used was contaminated with oversulfated chondroitin sulfate (OSCS) and
the source originated in China. It is not sure whether the contamination was intentional or
due to faulty processing of pig intestines55, 56.
Warfarin suffers from a narrow therapeutic index and many drug–drug or drug–food
interactions. Clinically used warfarin is a racemic mixture of R- and S- enantiomers, with
the R- enantiomer being more active. However it is metabolized more quickly than the Senantiomer. Single nucleotide polymorphisms (SNP‘s) in the gene encoding the enzyme
that metabolizes S- warfarin have been found which translate to significantly enhance
anticoagulation effect57-60. From 1990 to 2000, warfarin was ranked in the top ten for the
most number of serious and adverse events received by the FDA. Also in 2006, a ―black
box‖ warning was placed on warfarin by FDA related to its high risk of bleeding61, 62.

1.5.2 Direct Thrombin Inhibitors (DTI)
These molecules inhibit thrombin directly either through the active site or by an allosteric
mechanism of action. A major advantage of DTI‘s are that both circulating and clot
bound thrombin can be theoretically inhibited.
These are classified into naturally occurring compounds and synthetic compounds.
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1.5.2.1 Naturally occurring compounds
Hirudin was extracted from the salivary glands of the medicinal leech Hirudo
medicinalis in 1957. It is a polypeptide having 60 residues and is the most potent DTI
known till date having an Ki of ~20 fM. The primary sequence of hirudin has a sulfated
Tyr63(Figure 11). The binding of hirudin to thrombin is a slow process involving many
steps63.
Recombinant hirudins were made due to the high affinity of natural hirudin and differ at
only the three residues in the carboxyl terminus from hirudin. These recombinant
peptides (desiuridin, lepiuridin and bivaluridin) have Ki values of 60 fM, 200 fM and 1-2
nM64, 65. These molecules are bivalent thrombin inhibitors binding to the exosite-I and the
hydrophobic region near the active site.
Triabin is also another natural peptide that inhibits thrombin66.Nazumamide A,
A90720A are also natural products that have an arginine which recognize Asp189 in the
S1 specificity pocket of thrombin67, 68.
Theromin, a 67 amino acid peptide produced by the Rhynchobdellid leech, is the most
potent inhibitor of thrombin described till date (Ki = 12 ± 5 fM). The molecule had no
sequence homology with any other animal thrombin inhibitor characterized so far. It is
suggested that dimerization is required to give the protein an active folded configuration
that can bind to thrombin; however, the monomers are found to have inhibitory activity69.
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Figure 11

The sequence of naturally occurring hirudin. Recombinant hirudins do

not have a sulfate at Tyr63. The residues in red consist of the C-terminal exosite-1
recognition sequence and the residues in blue recognize the active site. (Figure adapted
from Rydel, T. J.; Ravichandran, K. G.; Tulinsky, A.; Bode, W.; Huber, R.; Roitsch, C.;
Fenton, J. W.,2nd The structure of a complex of recombinant hirudin and human alphathrombin. Science 1990, 249, 277-280.

1.5.2.2 Synthetic compounds
1.5.2.2.1

Irreversible Covalent Inhibitors

The peptide chloromethyl ketone D-Phe-Pro-Arg-CH2Cl (PPACK, 1) is used as an
affinity label for the active site of thrombin. It irreversibly acylates His57 of the catalytic
triad and inhibits thrombin70. However these molecules show no selectivity over other
serine proteases.
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1.5.2.2.2

Reversible Covalent Inhibitors

These class of molecules have an electrophillic moiety (serine trap), which is susceptible
to attack by the active site serine forming a reversible hemiacetal. Several electrophillic
groups which have been used are ketones, trifluoromethyl ketones, α-diketones, α-keto
heterocycles, α-keto amides, α-keto esters, organoboronic acids and organophosphonic
acids71-73. Some of the molecules under clinical evaluation are compound 2 (GYKI14766, Ki = 1.2 nM), compound 3 (CVS-1123), compound 4 (DUP-714, Ki = 40 pM)7477

.

However these compounds have a reactive functional group, which may make it less
selective against other coagulation proteases, more prone to metabolism and more toxic.

24

MeOOC
NH
N

N

HN
O
O

NH

O
O

O
OHC

H

H
N

NH
H

CHO

HN
NH 2

HN

CVS-1123

GYKI-14766
2

3

N

H
N

NH 2
HN

OH
B

HN

O

O

OH

O
NH

DUP 414
4

H2 N
NH

1.5.2.2.3

Reversible Non – Covalent Inhibitors

The lack of any serine trap is a characteristic of non covalent DTI‘s. This reduces a
potential for toxicity and the molecule can bind to the enzyme subsites by electrostatic
and hydrophobic interactions. Due to these reasons, several research groups have
concentrated their work on this class of compounds147.
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1.5.2.2.3.1

Guanidine or Amidine based molecules

The first compounds developed, compound 6 (NAPAP, Ki = 6 nM), and compound 7
(argatroban, Ki = 39 nM) were derived from the arginine derivative N-α-tosylarginine
methyl ester (TAME, 5)78-80. All of the molecules in this class have a guanidine or
arginine in its P1 position, which was based on the rationale to have binding interactions
with Asp189 in the S1 pocket of the protease. Argatroban was the first rationally designed
DTI to reach the clinic, however it is not orally bioavailable due to the highly basic
guanidine moiety.
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NH2

The researchers at Astra Zeneca developed compound 8 (inogatran, Ki = 15 nM)81.
Systematic modifications resulted in compound 9 (melagatran, Ki = 2 nM)82,

83

. The

benzamidino group of melagatran goes in the S1 pocket, while the azetidine and the
cyclohexyl ring are buried in the S2 and S3 pockets. Due to the low oral bioavailability of
melagatran, compound 10 (ximelagatran) was developed as a prodrug84, 85. Ximelagatran
is transformed to melagatran by two intermediates, which involves hydrolysis of the ester
and reduction of the amidoxime group. Due to the increased hydrophobicity of
ximelagatran, it was found to be more orally available. Despite the high efficacy and
bleeding profile of ximelagatran in clinical trials, FDA rejected its approval due to its off
target hepatotoxicity.

O
O
N
N

HN

HN
O
O
NH
NH
COOH

HN

NH

NH

COOH
H 2N

NH2

INOGATRAN

MELAGATRAN

8

9

27

O

N

HN
O

NH
NH

CO 2Et
HOHN

XIMELAGATRAN
10

Boehringer Ingelheim developed compound 11 (dabigatran etexilat), which is a prodrug
of 12 (dabigatran, Ki = 4.5 nM)86. It is acted upon by esterases in vivo to generate
dabigatran. It is based on a 1,2,5 trisubstituted benzimidazole core scaffold. The molecule
is under advanced phases of clinical trials. In the Bistro I and II study dabigatran etexilat
demonstrated an acceptable safety profile and satisfactory antithrombotic potential87, 88.
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Compound 13 (UK 156,406, Ki = 0.46 nM) developed by Allen et al. was modified from
the lead argatroban89. The molecule had a tetrahydroisoquinoline group at P3 and a
carboxylic acid and a olefin residue in the piperidine moiety at P2. The changes resulted
in good oral bioavailability and the drug is in clinical trials89.
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The most potent synthetic inhibitor till date is compound 14 (LB-30812, Ki = 3 pM).
However due to the basic amidine group at P1 position, it is only moderately
bioavailable90.
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The BMS group used a piperidine unit at P1 to obtain compound 15 (BMS-189090, Ki =
3.6 nM), which is in preclinical development91.
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1.5.2.2.3.2

Non – amidine based molecules

The realization that the lipohilicity of the S1 pocket can be utilized for designing
inhibitors spurred an interest for compounds which have a lesser basic P1 group and
thereby be more orally bioavailable.
Compound 16 (SSR-182289A, Ki = 31 nM) is an extremely potent DTI whose lead was
argatroban. The P1 unit was replaced from guanidine in argatroban to a 3-aminopyridine
moiety and thereby the molecule is orally bioavailable. The compound is under phase-II
clinical trials92.
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Oh et al. designed the compound 17 (LB-30057, Ki =0.38 nM) which has a less basic
benzamidrazone in its P1 position. Also, it was shown to be orally active in dog models93.
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Kane et al. optimized the P1 position of argatroban utilizing the lipophilicity of the S1
pocket which has an Ala190 in addition to an Asp189. A lipophilic group benzothiazole was
used in the P1 position to obtain compound 18 (CGH 752, Ki = 0.026 nM)94.
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Sanderson et al. used 3-amino-2-pyridinone and 5-amino-6-pyridinone acetamide
scaffolds with an amino pyridine in P1 to get compound 19 (Ki = 0.85 nM) with an
improved pharmacokinetic profile95.
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Replacement of the pyridinone core with a more stable 3-alkylaminopyrazinone biostere
lead to compound 20 (L-375,378, Ki = 0.8 nM), which was further selected for clinical
trials96.
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1.6

Factor Xa Inhibitors

1.6.1 Synthetic Direct Non Covalent fXa inhibitors
Initially the first molecules identified were based on bisbenzamidines. The early
molecules originated were from thrombin inhibitor programs. The presence of basic
amidine groups on the P1 and the P4 positions of the scaffold made the compounds
poorly bioavailable. The first bisbenzamidines, which were identified as potent molecules
were compound 21 (DABE, Ki = 573 nM) and compound 22 (BABCH, Ki = 610
nM)116,117.
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Upon replacing one of the basic benzamidine/amidine moieties on the scaffold (either P1
or P4) with a lesser basic functional group resulted in higher oral bioavailability. But this
lowered the selectivity of the molecule towards fXa against other serine proteases.
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However, when the remaining benzamidine/amidine was substituted with another lesser
basic group highly potent, selective and orally bioavailable inhibitors were discovered.
Compound 23 (rivaroxaban, Ki = 2.1 nM) is currently the most advanced inhibitor in
clinical trials. In 2008, it was approved by the European commission for prevention of
venous thromboembolism (VTE) after total knee and hip replacement. The cocrystal
structure of with fXa (PDB code 2W26) shows that the oxazolidinone ring serves as the
core to direct the morpholine residue into the S4 pocket and the chlorothiophene into the
S1 pocket. Hydrogen bonds are seen between amide N-H of Gly219 and the carbonyl of
the oxazolidinone and between the carbonyl of Gly219 and the N-H of the thiophene
carboxamide118-121. In the S1 pocket the important interaction is between the chlorine and
the aromatic ring of Try228.
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Phenylglycinamide series of compounds with a rigid P4 unit and an indole in the P1
position displayed Ki values in the lower nM range. Among the series, compound 24
(LY-517717, Ki = 4.6 nM) showed 25% to 82% oral bioavailability and a 1000 fold
selectivity against other serine proteases. The compound was advanced to phase-II
clinical trials122,123.
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Among a set of compounds with a pyrazole scaffold and benzamidine as the P1
substituent, replacement of the P1 substituent with less basic or neutral scaffolds was
explored. It was found that lowering the pKa of the P1 position systematically improved
oral bioavailability. Substituting the P1 with a 3-aminobenzisoxazole moiety and
optimizing the P4 with dimethylaminomethylimidazole gave the compound 25
(razaxaban, Ki = 0.19 nM). The cocrystal structure of 25 with fXa shows that the
aminobenzisoxazole binds to the S1 pocket and the amino group interacts with Asp189
and the carbonyl of Gly218. The imidazole binds in the S4 pocket with a hydrogen bond to
Glu97. The compound passed phase-II trials; however, it was withdrawn for undisclosed
reasons124,125.
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There were concerns about the pyrazole carboxamide core present in compound. It might
hydrolyze in physiological conditions to release a potentially mutagenic biarylaniline.
One of the approaches to this issue was to replace the nitrogen of the carboxamide
scaffold with a methylene group. Further optimization lead to compound 26 (apixaban,
Ki = 0.08 nM). The compound was found to be highly selective for fXa against thrombin
and trypsin. The cocrystal structure of compound bound to fXa (PDB code 2PI6) showed
that the p-methoxy group goes in the S1 pocket, the pyrazole interacts with Gln192 and the
carboxamide carbonyl interacts with Gly216. The lactam is found in the S4 pocket
interacting with Tyr99 and Phe174. This compound showed an oral bioavailability of 58%
and has advanced to phase-III trials126,127.
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In a set of amino acid derivatives of fXa inhibitors synthesized, a compound was reported
to have a Ki of 9.4 nM. Removal of the phenyl group and SAR exploration around P4
lead to the compound 27 (otamixaban, Ki = 0.4 nM). Moreover, the compound was found
to be highly selective against other serine proteases. The cocrystal structure of compound
27 bound to fXa (PDB code 1KSN) showed that the benzamidine is in the S1 pocket and
the heterobiaryl group is in the P4 pocket. A hydrogen bond is found between the
carbonyl of the amide and N-H of Gly219. The compound was advanced to phase-II
clinical trials128,129.
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In a series of pyrazoles, compound 28 (DPC-423, Ki = 0.15 nM) showed an improved
pharmacokinetic profile compared to others in the series. It has a benzylamine in the P1
position and a substituted phenyl group in the P4 position and a pyrazole carboxamide
core. Compound 28 showed an oral bioavailability of 57%. The molecule was selective
against other coagulation proteases however, not against trypsin and kallikrein. DPC-423
is in phase-I clinical trials130.
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CF3

Compound 29 (KFA-1411, Ki = 1.7 nM) has been found to be a highly potent and
selective inhibitor of fXa. It has an amidine moiety both at the P1 and P4 positions.
Compound 29 is under phase-I clinical trials131.
Compound 30 (DX-9065a, Ki = 41 nM) is a naphthyl-amidine based fXa inhibitor, which
inhibits free fXa, clot bound fXa, fXa in the prothrombinase complex and clot bound
prothrombinase complex. The naphthyl-amidine moiety binds to the Asp189 in the S1
pocket and the pyrrolidine goes to the S4 pocket. However it is not orally bioavailable
and its prodrug DU-176b is in phase-II clinical trials132.
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1.6.2 Limitations of Direct Inhibitors
The hirudins are associated with major bleeding episodes, which limits their use in
patients refractory to UFH134, 135. As hirudins are foreign peptides, they are potentially
immunogenic and may cause life threatening disorders. Due to the high potency of
hirudins for thrombin, there is no antidote for their use49. As a result bivalirudin was
developed however, it has a shorter half life (25 min) because thrombin cleaves its Arg3Pro4 bond. Argatroban, approved for patients having a high risk for HIT, has a shorter
half life and is associated with bleeding risks. Moreover, a significant limitation for the
direct inhibitors is the presence of the highly basic guanidine or the arginine moiety
which doesn‘t make them orally bioavailable. To counteract this problem ximelagatran
was developed as a pro-drug of melagatran and was approved for clinical use in Europe.
But US FDA rejected its application in 2004 due to concerns of hepatotoxicity136. Recent
studies also show that inhibitors which use a basic group as the P1 moiety may cause
degranulation of mast cells resulting in histamine release136,137. Therefore, a lot more
challenges persist to develop a direct inhibitor which addresses all these issues.

1.7

Rationale for the work

With a goal of developing dual fXa and thrombin inhibitors, which can mimic heparins
but are less polyanionic and more hydrophobic, our lab had designed sulfated
dehydropolymers (DHP) from enzymatic coupling of 4-hydroxy cinnamic acids followed
by the chemical sulfation of the free phenolic groups giving sulfated dehydropolymers.
An example of such a molecule is CDSO3 (Figure 12). The average molecular weight of
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CDSO3 was found to be 3320 and the range of oligomeric chain length varied from 5-13
monomeric units. CDSO3 was found to contain an average of 0.4 sulfate groups per
monomer37.
Inhibition studies on thrombin and fXa in presence and absence of AT indicated that
CDSO3 inhibited both the proteases preferentially by a direct mechanism, i.e. in the
absence of AT with an IC50 value of 18 nM and 34 nM for thrombin and fXa,
respectively. Michaelis – Menten kinetics indicated that Km was unaffected in the
presence of these inhibitors, whereas Vmax decreased steadily. Thus, CDSO3 did not
affect the formation of the Michaelis – Menten complex, while the forward rate constant
of hydrolysis of the substrate (kcat or k2) is significantly reduced. These results suggest a
non – competitive mechanism of enzyme inhibition, wherein the catalytic apparatus of
the enzyme is disrupted by an allosteric mechanism36. Moreover, in whole blood and
plasma coagulation assays (PT and APPT), CDSO3 displayed anticoagulation properties
similar to the clinically used anticoagulant enoxaparin138.
Being a polyanionic molecule, CDSO3 can theoretically bind either to the exosite-I or
exosite-II of thrombin, both of which are known to bind anionic molecules. Competitive
binding studies with exosite-I and exosite-II ligands indicate that CDSO3 binds in or near
the anion binding exosite-II36. In a similar manner CDSO3 is expected to bind at the
heparin binding exosite-II in fXa, as the exosite-I is cationic in character.
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Figure 12

Preparation of CDSO3. The oxidative polymerization of caffeic acid by

horseradish peroxidase and sulfation by triethyamine sulfur trioxide complex gives the
heterogeneous CDSO3. The β-5 and β-O-4 linkages are highlighted.

CDSO3 has been characterized as of having β-5, β-O-4, β-β and 5-5 inter-monomeric
linkages where the β-5 and β-O-4 are predominant in its structure. In addition, CDSO3 is
heterogeneous with variable numbers of sulfates, carboxylates, chiral centers and variable
chain length. To study the role of these structural units require a large library of aromatic
molecules with multiple sulfates, carboxylates and stereo-centers. Chemically, the
structure of CDSO3 can be thought of as dihydrobenzofuran and phenoxypropanoic acid
units, which could be successively, alternatively or randomly linked with each other. We
hypothesized that delineation of key structural features of CDSO3 can be achieved by
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accessing the importance of each contributing units, i.e., dihydrobenzofuran and
phenoxypropanoic acid individually. Thus, we sought initially to synthesize a library of
dihydrobenzofuran-like molecules and evaluate their inhibitory potential towards the two
proteases – factor Xa and thrombin.
The β-5 monomer of CDSO3 is a dihydrobenzofuran moiety with a carboxylate at
position-3, sulfate at position-7 and two stereo-centers at C-2 and C-3. With a goal of
simplifying the structure, we removed the chiral-centers and introduced aromaticity to
arrive at a benzofuran unit. Keeping an eye on the synthetic accessibility resulted in 5,6dihydroxy-benzofuran-3-carboxylic acid ethyl ester (1E, Figure 13).
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Figure 13

The rationale behind synthesis of monomer 1E

Simplify structure
-Remove chirality

Synthetically
accessible
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Monomer 1E served as the starting point to differentially introduce multiple sulfate and
carboxylate groups on the benzofuran scaffold so as to study the structure-activity
relationship (SAR) (Figure 14). The hydroxyl groups can be sulfated to their O-sulfates
and the ethyl ester can be hydrolyzed to the corresponding carboxylic acid. In compounds
where only one phenolic sulfate is present, the other hydroxyl group was sought to be
protected as a methoxy group. Also we sought to study the effect of carbon homologation
at the C-3 position, wherein the distance between the C-3 carboxylic acid and the ring
was to be varied by one carbon. In this manner, a small focused library of compounds
was designed.
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Figure 14

The SAR sought to be explored around compound 1E
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Synthesis and Biological Evaluation of β-5 like Monomers

2

2.1

Synthesis of β-5 like monomers

2.1.1

Synthesis of ethyl ester 1E

The initial ethyl ester monomer 1E was synthesized by a laccase mediated oxidative
coupling of catechol and ethyl-4-chloro acetoacetate in presence of the Lewis acid
scandium triflate and SDS to solubilize the reactants in the aqueous buffer139. 43% yield of
compound 1E was obtained, which is comparable to the literature yield of 46%. The
compound was characterized by both 1H and

13

C NMR, where in the characteristic two

aromatic protons of 1E were distinguished.
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2.1.2

2

1E

Synthesis of 1A

The ethyl ester of 1E was sought to be hydrolyzed under traditional basic hydrolytic
conditions in which either NaOH or LiOH in ethanol or methanol is used to expose the
carboxylate group. However, these conditions gave a mixture of undesirable degradative
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products as had been observed by 1H NMR (Table 1). It is possible that metal-catalyzed oquinol oxidation to the corresponding o-quinone, which might have further facilitated the
benzofuran ring opening, resulting in degradation.
HO

O
CH 3

OH-

Degradation products

HO
O
O

1E

Table 1

Reagents and conditions tried for synthesis of 1A

Reagents and conditions

Outcome

NaOH/EtOH, 600C

Degradation

NaOH/EtOH, 00C

Degradation

LiOH/MeOH, 00C

Degradation

Na t-BuO, H2O, DMSO

Degradation

Then an alternative synthetic plan was devised. The catechol was protected with
dichlorodiphenylmethane followed by hydrolysis of the ethyl ester under basic hydrolytic
conditions in one pot and isolation of the protected acid 8 in 63% overall yield. 1H NMR
indicated the presence of the carboxylic acid proton at 12.97 δ and twelve aromatic protons
in 7.36-7.56 δ suggesting the formation of 8. Then, under aqueous acidic conditions, which
is described in literature for the removal of the diphenylmethane protecting group, the
compound 1A was isolated in 69% yield.
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2.1.3

Synthesis of 6ES

6ES was synthesized by a microwave based sulfation protocol developed in our lab that
uses trimethylamine sulfur trioxide complex and triethylamine base in acetonitrile under
microwave, followed by purification using size-exclusion chromatography140. The
trialkylamine salt of the sulfate was exchanged to the sodium salt using cation-exchange
columns to give the corresponding sulfate 6ES in 90% yield. Characterization was
performed by using 1H NMR wherein a characteristic downfield shift of the aromatic
protons is observed when two sulfates are introduced in the product. These protons are
seen at 7.42-7.73 δ, whereas they resonate at 6.95-7.37 δ in the un-sulfated precursor 1E.
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2.1.4

Synthesis of 6AS

Conversion of the ester into the corresponding acid worked with the anhydrous ester
hydrolysis protocol previously used in our lab for compounds with sulfates. The method
uses potassium t-butoxide in anhydrous DMSO having one equivalent of H2O to hydrolyze
the ester, followed by size-exclusion chromatography to purify the compound141.
Traditional hydrolytic conditions like NaOH in ethanol and HCl in ethanol resulted in the
breakdown of the sulfate groups. Compound 6AS was obtained in 90% yield and was
characterized by 1H and 13C NMR, which showed the absence of an ester group, and mass
spectrometry, which indicates the parent ion peak.
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2.1.5

Synthesis of sulfates 4ES and 5ES

To protect either one of the phenolic groups as a methoxy group, the ethyl ester monomer
1E was treated with methyl iodide and cesium carbonate in DMF to give the regioisomers
2E and 3E in 53% and 30% yield respectively.

HO
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CH3
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HO
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O

CH 3
HO

CH 3
O

O

O

O

O

O

O

2E

1E

3E

According to literature, the regioisomer 2E would be the product in the highest yield due
to the increased acidity of the 6-hydroxy group when compared with the 5-hydroxy group.
Interestingly, the Rf values of the regioisomers were different on silica, hence they could
be purified using flash chromatography on silica. 1H and

13

C spectra for the compounds

indicated an obvious difference in the ppm values of the isomers. A NOESY experiment,
which correlates proton-proton through space coupling, was used to confirm the structure
of 2E. The 1H NMR spectrum of 2E shows peaks at 7.44, 6.95, 5.58, 4.48, 3.96, 2.75 and
1.46 δ. The NOESY spectrum shows cross-peaks between 7.44 and 1.46 δ protons,
suggesting that the aromatic proton ‗a‘ is in close proximity to ester –CH3- ‗g‘ (Figure 15).
This correlation was used to assign the aromatic resonances and confirm the compound
2E.
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1

Figure 15

H assignments and NOESY correlation for compound 2E
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Sulfates were introduced onto the free phenolic groups of 2E and 3E using the basecatalyzed, microwave- assisted protocol described earlier to give 4ES and 5ES in yields of
94% and 92%, respectively. 1H NMR was used to confirm the compounds in which a shift
of one of the aromatic protons that is adjacent to the introduced sulfate group is observed
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(7.97 δ in 4ES when compared to 7.44 δ in 2E and 7.13 δ in 5ES when compared to 7.40 δ
in 3E).

RO
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CH 3
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Me3N:SO3, Et3N

CH 3

MeCN
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R'O
O

O

O

O

4ES: R=Me, R'=SO3- Na+
5ES: R=SO3- Na+, R'=Me

2E: R=Me, R'=H
3E: R=H, R'=Me

2.1.6

Synthesis of 4AS and 5AS

The ethyl esters of 4ES and 5ES were hydrolyzed using the anhydrous ester hydrolysis
protocol using potassium t-butoxide in DMSO. Compounds 4AS and 5AS were isolated in
yields of 90% each and were confirmed by 1H,

13

C NMR and mass spectroscopy. The

absence of the ester protons and carbons in the 1H and 13C NMR was used to confirm the
compounds. Moreover, mass spectrometry indicated the parent ion peak of these
compounds.
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2.1.7

Synthesis of 2A

The hydrolysis of the ethyl ester in compound 2E occurred uneventfully under basic
hydrolytic conditions to give compound 2A in 90% yield. The compound was confirmed
by 1H and

13

C NMR wherein the ester protons and carbons were absent. Also, mass

spectrometry indicated the parent ion peak of the product 2A.
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O

2.1.8

Synthesis of 1XS

To make compound 1XS, a synthetic plan was devised in which the ethyl ester in 2E was
reduced to an alcohol by a hydride delivering agent and then sulfates are introduced on
both of the hydroxyl groups. The compound 1X was isolated on reduction of 1E with LAH
in a yield of 84%. The structure of 1X was confirmed by 1H and

13

C NMR wherein the

characteristic benzylic protons at 4.65 δ are observed.
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However, sulfation of 1X to obtain 1XS did not succeed as 1XS was found to be unstable
in aqueous solution. The reason for this unstability is unclear at this time.
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OSO3- Na+

2.1.9

Synthesis of 8ES and 8AS

To study the effect of homologation by an additional carbon at the C-3 position, a
synthetic strategy was envisioned such that disconnection of the CH2-COOH bond of the
target 8AS by the Wittig reaction leads to the benzofuran-3-aldehyde precursor 12 and
methoxymethylene triphenylphosphorane (MMTPP). The synthesis of 12 would
commence from the compound 2E by reduction of the ester to the aldehyde 12 by a
sterically hindered hydride delivery agent, followed by protection of the phenolic group
and Wittig with MMTPP to give the compound 11. The acidic hydrolysis of the Witting
derivative to give the aldehyde, followed by sulfation of the free phenolic group and
oxidation of the aldehyde to the corresponding carboxylic acid would lead to 8ES and 8AS
(Figure 16).

57

Figure 16

Reterosynthetic analysis and scheme for 8ES and 8AS
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The reduction of the compound 2E to the aldehyde derivative 10 proved to be problematic
as no reaction occurred with the common hydride reducing agent DIBAL. Hence for
synthesizing compound 10, one more step was added in the sequence: reduction of the
ester to the alcohol with LAH and oxidation of the alcohol to the aldehyde. The protection
of the phenol to a silyl derivative was carried out before the reduction because of ease of
handling the now protected derivative 9 (Figure 17).
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Figure 17
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O

O
CH3

CH3

2)

HO

2E

O

O

1) TBDMS protection
(H -)

TBDMSO

O

(O)

CH3

TBDMSO

CO2Et

9

CH2OH

10

CHO

The compound 2E was converted into the silyl derivative and the ester was reduced into
the alcohol 9 using LAH. Compound 9 was obtained in 80% yield and confirmed by 1H
NMR, which shows the presence of the -CH2- protons at 4.69 δ. However, the oxidation of
compound 9 to the aldehyde 10 proved to be difficult with common mild oxidants like
chromate salts and Dess Martin periodinane, giving unsatisfactory yields. Experiments
with TEMPO (2,2,6,6-Tetramethylpiperidine-1-oxyl )142 gave satisfactory yields to give the
compound 10 (Table 2), which was characterized by 1H NMR. The characteristic aldehyde
proton at 10.15 δ and the absence of the –CH2- protons observed in 9 were used to confirm
the product 10.
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Table 2

Optimization of Oxidation Conditions
Reagent

Yield

MnO2

No conversion

PCC, DCM, rt

10%

PCC, DCM, μw

17%

DMP, DCM

40%

TEMPO, NCS, DCM

80%

The Wittig reaction proceeded with the aldehyde to obtain a compound 11 that was a
mixture of both isomers. However the the acidic hydrolysis of 11 resulted in degradation.

2.1.10 Synthesis of 7ES
Due to the degradation of the Wittig derivative 11, an alternative approach was devised in
which, instead of a one carbon homologation, a two carbon increase in the linkage between
the ester and the aromatic scaffold was devised to give the new target 7ES. Again
disconnection of the target 7ES at the CH2-CH2 bond by Wittig and subsequent
hydrogenation of the olefin gives compound 10 and (carbethoxy) methylenetriphenyl
phosphorane (CEMTPP) (Figure 18).
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Figure 18

Retrosynthetic analysis of 7ES
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Then, from compound 10, the scheme described above could be followed. The Wittig
reaction occurred and the trans isomer was isolated from the reaction mixture in 96% yield.
The double bond was reduced by hydrogen over palladium to give the crude 12. 1H NMR
of the crude 12 indicated a mixture, which suggested that partial de-silylation had
occurred. The silyl group was subsequently removed using TBAF to give the compound
7E. The structure of 7E was determined by 1H NMR, wherein the four protons of -CH2CH2- were distinctly observed at 2.59 and 2.87 δ. The ester protons were also distinguished
at 1.22 and 4.12 δ. Following, microwave-based sulfation gave the compound 7ES in 39%
yield and was confirmed by 1H NMR wherein the downshifted aromatic proton which
resonated at 7.50 δ when compared to 6.94 δ for the unsulfated precursor 7E.
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2.1.11 Synthesis of 7AS
The ethyl ester present in 7ES was subsequently hydrolyzed by the anhydrous ester
hydrolysis protocol to give the compound 7AS in 91% yield. The compound was
confirmed by 1H NMR, wherein the absence of the ester protons confirmed the presence of
7AS. Moreover, mass spectrometry indicated the parent ion peak of 7AS.
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2.1.12 Synthesis of 7A
Under basic hydrolytic conditions the ethyl ester present in compound 7E was hydrolyzed
to compound 7A in 50% yield. The structure of 7A was confirmed by 1H,

13

C NMR and

mass spectrometry.
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Direct inhibition of thrombin and factor Xa (Work performed by Dr. Liang)

To determine whether the β-5-like monomers synthesized inhibit the coagulation proteases
– fXa and thrombin, the residual enzymatic activity of the proteases was measured by
following spectrophotometrically the initial rate of hydrolysis of the appropriate
chromogenic substrate. Spectrozyme TH and S-2772 were used as substrates for thrombin
and fXa. Relative residual protease activity (in %) at each concentration of the β-5 like
monomer was calculated as a ratio of the slopes measured in the presence of the inhibitor
to that in its absence37. From the residual protease activity, the percentage of the enzyme
inhibited was determined.
Out of the seventeen molecules screened, only seven of them (1A, 2A, 4AS, 5AS, 6AS,
7A and 7AS) exhibited any inhibition potential (Figure 19). The minimal concentration of
these compounds necessary to display inhibition was approximately 400 μM. All the other
derivatives in the library were found to be inactive below 4.3 mM.
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Figure 19

Inhibition of Thrombin (upper plot) and Factor Xa (lower plot) by the

β-5 like monomers 1A, 2A, 4AS, 5AS, 6AS, 7A and 7AS. The compounds were present
at 2.9 mM (thrombin) or 2.6 mM (fXa), except for the asterisk (*) labeled cases where
concentration was 4.3 mM. The standard error in the experiments was less than 10%.
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2.3

Mechanism of Factor Xa Inhibition (Work performed by Dr. Liang)

To determine the mechanism of inhibition of factor Xa by the synthesized β-5-like
monomers, the kinetics of S-2772 hydrolysis by factor Xa in the presence and the absence
of the compound 5AS were determined. The initial rate of hydrolysis varied in a
hyperbolic manner with the concentration of the substrate from which the Michaelis
constant (KM) and maximal velocity of the reaction (VMAX) were derived (Figure 20). The
KM and VMAX for S-2772 in the absence of compound 5AS was found to be 441±86 μM
and 197±22 mAUmin-1μM-1 respectively. In the presence of 5AS the values changed to
61±13 μM and 54±4 mAUmin-1μM-1 respectively.

Figure 20

Hydrolysis of substrate S-2772 by factor Xa in the presence () and

absence () of 2.6 mM 5AS. The solid lines represent the fits to Michaelis – Menten
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2.4

Discussion

Of the seventeen β-5 like monomers made, only 1A, 2A, 4AS, 5AS, 6AS, 7A and 7AS
displayed inhibitory properties. This indicates that only selected monomeric units with
appropriate substitutions carry the property of direct inhibition of thrombin and factor Xa.
The minimal concentration required to display inhibition was 400 μM, which is fairly high.
However interesting structure-activity relationships could be deduced from the study.
All ester containing monomers exhibited no inhibition, suggesting an important role for the
–COO- group. Whereas no molecule displayed more than 40% inhibition of thrombin at
2.9 mM, at least four out of seven (4AS, 5AS, 6AS and 7A) inhibit factor Xa better
(>40%) at 2.6 mM. This suggests a slight preference of the benzofuran scaffold for
inhibition of factor Xa.
Importantly, inhibitors 5AS and 6AS display 86% and 75% inhibition of factor Xa
respectively, which is better than all the other inhibitors. This suggests a significant
selectivity of recognition of these molecules by the enzyme. The common pharmacophore
present in these two molecules is the 3-COO- and the 6-OSO3- unit, which is absent in all
the other molecules. Interestingly, the molecule 4AS, which is the regioisomer of 5AS,
only inhibits factor Xa 42%, when compared to 5AS (86%), supporting a preferential
recognition hypothesis. 5AS and 6AS more closely resemble the native CDSO3 dihydrobenzofuran monomer than molecules 7A and 7AS, which have a non-native extended
COO- bearing linker.
The decrease of the KM value from 441±86 μM to 61±13 μM and the VMAX from 197±22
mAUmin-1μM-1 to 54±4 mAUmin-1μM-1 for the hydrolysis of S-2772 by factor Xa in
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presence of 5AS indicate that in presence of the inhibitor the binding of the substrate to the
active site of the protease is significantly affected. Specifically the interaction of 5AS with
factor Xa results in a 7-fold increase in affinity of the substrate towards the enzyme and a
3.6 fold decrease in the catalytic rate of hydrolysis. Thereby, the presence of 5AS
introduces structural changes in the active site of factor Xa that alters the formation of the
factor Xa-S-2772 Michaelis complex as well as induces dysfunction of the catalytic
apparatus of the enzyme. Considering that the lead, i.e., CDSO3, binds to the exosite-II of
thrombin, these results support the hypothesis that these β-5-like monomers also inhibit
thrombin and factor Xa through exosite-II mediated allosteric dysfunction of the catalytic
triad.

2.5

Experimental section

2.5.1

General methods

Reagents/chemicals were purchased from Sigma-Aldrich (unless specified otherwise) and
used as supplied. Analytical thin layer chromatography (TLC) was performed using
UNIPLATETM silica gel GHLF 250 μm pre-coated plates (ANALTECH, Newark, DE)
with a fluorescence indicator (254 nm). Column chromatography was performed using
silica gel (60 Ao, 200-400 mesh, Sigma-Aldrich). Microwave-assisted sulfation reactions
were performed using CEM-Discover (Matthews, NC) synthesizer in sealed reaction
vessels (7 ml). The reaction condition was set to ramp to 100oC at 50 W and was
maintained by cooling with nitrogen at 45 psi.

67

Sephadex G10 chromatography and SP Sephadex-Na chromatography (cation exchange)
were performed using flex columns (KIMBLE/KONTES, Vineland, NJ) of dimensions
170 × 1.5 cm and 75 × 1.5 cm. Cation exchange was performed using 30 fold excess of
sodium ion equivalents. Samples were chromatographed at a controlled flow rate of 0.5
ml/min using water or 20% EtOH/H2O as the eluent. Fractions of 5 mL each were
collected and analyzed by RP-HPLC or capillary electrophoresis.
HPLC analysis was carried out on a Shimadzu chromatography system using Waters
Atlantis dC18 column (5 µm, 4.6 × 250mm). The mobile phase consisted of acetonitrile –
water mixture (2:8 v/v) run at a flow rate of 0.5 ml/min. Analysis was carried out using a
UV-VIS detector at 254 nm.
Capillary electrophoresis was performed using a P/ACE MDQTM Beckman capillary
electrophoresis system (Fullerton, CA). The experiments were performed at a constant
voltage of 8 kV and constant pressure of 0.1 psi. An uncoated fused silica capillary (I.D.
75 mm) of 31.2 cm total length with a 5 mm detection window at 21.0 cm length from the
injection point was used. During electrophoresis, the capillary was held at a constant
temperature of 25 °C. Sequential washes of 1 M HCl for 10 min, high purity water for 3
min, 1 M NaOH for 10 min and high purity water for 3 min at 20 psi were used to activate
a new capillary. Before each electrophoretic run, the capillary was rinsed with the run
buffer for 3 min at 20 psi. Run electrolytes containing 50 mM sodium phosphate buffer,
pH 3.0. Sample solution in deionized water was injected at the cathodic end using 0.5 psi
pressure for 5 s. Electrophoresis was monitored at the anodic end by following absorbance
at 254 nm.
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1

H NMR and

13

C NMR were recorded on Varian Mercury-300 MHz spectrometer in

CDCl3, DMSO-d6, CD3OD, acetone-d6, or D2O. All signals are reported in ppm with the
residual chloroform, DMSO, acetone, and H2O signals at 7.26, 2.50, 3.31, 2.05, and 4.79,
respectively, as standards. The data is reported as: chemical shifts (ppm), multiplicity (s =
singlet, d = doublet, t = triplet, m = multiplet), coupling constant(s) (Hz), and integration.
ESI mass spectra were recorded using a Micromass ZMD 4000 single quadrupole
spectrometer. Samples were dissolved in 5% formic acid in methanol and infused at a rate
of 10 μL/min. Mass scans were obtained in the range of 100-900 amu at a scan rate of 400
amu/s. Ionization conditions were optimized for each compound to maximize ionization of
the parent ion. The capillary voltage was varied between 3.0 and 5.0 V, while the cone
voltage ranged from 20 to 85 V. For all experiments the extractor voltage was set to 3.0,
the Rf lens voltage to 0.1 V, the source block temperature to 1000C and the desolvation
temperature to 1500C.
Proteins —Human coagulation factors Xa and IIa (-thrombin) were purchased from
Haematologic Technologies (Essex Junction, VT). Stock solutions of proteins were
prepared in 20 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl and 2.5
mM CaCl2 (AT and thrombin) or 5 mM MES buffer, pH 6.0 (factor Xa). Chromogenic
substrates Spectrozyme TH was purchased from American Diagnostica (Greenwich, CT),
while substrate Chromogenix S-2772 was from DiaPharma group, Inc (West Chester,
Ohio).
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2.5.2

Synthesis of 1E

To a solution of catechol 1 (550 mg, 5 mmol, 1.0 equiv) in sodium phosphate buffer (150
ml, 0.1 M, pH 7) were added laccase (25 mg, 500 U), chloro ethyl acetoacetate 2 (Alfa
Aesar) (1.385 ml, 10 mmol, 2.0 equiv), scandium triflate (492 mg, 1 mmol, 0.2 equiv), and
sodium dodecyl sulfate (Fischer Biotech) (288.38 mg, 1 mmol, 0.2 equiv). The reaction
mixture was vigorously stirred. After 4 hours the reaction mixture was acidified to pH 2
using HCl and filtered on celite. The residue was dissolved in ethyl acetate, dried using an.
Na2SO4 and concentrated to a powder, which was purified by flash chromatography on
silica gel (30% EtOAc in hexanes) to give 1E (510 mg, 2.16 mmol, 43%). 1H NMR
(acetone-d6, 300 MHz) δ 1.36 (t, J =3 Hz, 3H, CH3), 2.63 (s, 3H, CH3), 4.31 (q, J =6 Hz,
2H, CH2), 6.95 (s, 1H, Ar-H), 7.37 (s, 1H, Ar-H), 7.99 (s, 2H, OH) (Figure 21). 13C NMR
(CDCl3) δ 14.79, 14.96, 60.54, 98.53, 106.62, 108.83, 117.56, 144.09, 144.92, 147.79,
161.79, 164.48 (Figure 22).
2.5.3

Synthesis of 1A

To 1E (100 mg, 0.423 mmol, 1.0 equiv) in a two necked flask fitted with a reflux
condenser was added dichlorodiphenyl methane (0.08 ml, 0.423 mmol, 1.0 equiv) under
nitrogen. The reaction mixture was heated to 1800C. After 30 minutes the reaction mixture
was allowed to cool to room temperature and ethanol (4.0 ml) and sodium hydroxide (0.8
ml from 2N soln) were added, and the mixture was heated to 800C. After 16 hours the
reaction mixture was allowed to cool to room temperature and quenched with 2N HCl and
extracted with ether and ethyl acetate. The organics were dried (Na2SO4), concentrated and
purified using flash chromatography on silica gel (20-90% EtOAc in hexanes) to give 8
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(100 mg, 0.27 mmol, 63%). 1H NMR (DMSO-d6, 300 MHz) δ 2.63 (s, 3H, CH3), 7.36-7.56
(m, 12H), 12.97 (s, 1H, OH) (Figure 23).
To 8 (78.0 mg, 0.209 mmol, 1.0 equiv) in a two-necked flask fitted with a reflux condenser
was added 80% AcOH/H2O (3 ml) and the mixture was refluxed. After 16 hours the
mixture was cooled to room temperature and extracted with water and ethyl acetate. The
organic extract was dried (Na2SO4), concentrated in vacuo and purified using flash
chromatography on silica gel (10-60% EtOAc in hexanes) to give 1A (30 mg, 0.144 mmol,
69%). 1H NMR (acetone-d6, 300 MHz) δ 2.67 (s, 3H, CH3), 6.97 (s, 1H, Ar-H), 7.41 (s, 1H,
Ar-H) (Figure 24).

13

C NMR 13.63, 97.64, 106.38, 108.91, 118.62, 143.11, 144.11,

148.17, 161.89, 164.93 (Figure 25). ESI (-ve) m/z calcd for C10H8O5 [(M-H)-)] 207.04,
found 206.88 (Figure 26). Capillary electropherogram (Figure 57B)
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2.5.4

Synthesis of 6ES

To a solution of 1E (30 mg, 0.127 mmol, 1.0 equiv) in acetonitrile (0.8 ml) in a microwave
tube were added triethylamine (0.31 ml, 2.286 mmol, 18.0 equiv) and trimethylaminesulfur trioxide complex (282.5 mg, 2.03 mmol, 16.0 equiv) under nitrogen. The mixture
was exposed to microwaves (50 W, 30 min, 1000C). The process was repeated, the
resulting mixture was concentrated in vacuo and 2 ml of water was added with stirring.
The mixture was loaded onto a Sephadex G-10 column and was chromatographed with
20% EtOH-water as eluent. Fractions were monitored using reverse phase HPLC, pooled
according to similarity of migration profiles, concentrated and reloaded onto a SP
Sephadex C-25 column. Appropriate fractions were pooled and lyophilized to give 6ES
(101 mg, 0.23 mmol, 90%). 1H NMR (D2O, 300 MHz) δ 1.23 (t, J =6 Hz, 3H, CH3), 2.34
(s, 3H, CH3), 4.13 (q, J =9 Hz, 2H, CH2), 7.42 (s, 1H, Ar-H), 7.73 (s, 1H, Ar-H) (Figure
27).

2.5.5

Synthesis of 6AS

6ES (50 mg, 0.114 mmol, 1.0 equiv) was dissolved in DMSO (1.1 ml). To this solution
were added potassium tert-butoxide (TCI AMERICA) (38.4 mg, 0.342 mmol, 3.0 equiv)
and H2O (3.1 μl, 0.171 mmol, 1.5 equiv) under N2. The reaction was monitored on reverse
phase HPLC and after 3 hours dibasic sodium phosphate (161.8 mg, 1.14 mmol, 10.0
equiv) was added and stirred for an additional 30 minutes. The reaction mixture was
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions
containing the product were identified using a reverse phase HPLC, lyophilized to obtain
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6AS (44.51 mg, 0.10 mmol, 90%). 1H NMR (D2O, 300 MHz) δ 7.46 (s, 1H, Ar-H), 7.77 (s,
1H, Ar-H), 2.54 (s, 3H, CH3) (Figure 28).

13

C NMR 13.56, 105.84, 114.05, 114.87,

125.63, 139.94, 140.16, 150.13, 162.27, 172.10 (Figure 29). ESI (+ve) m/z calcd for
C10H5Na3O11S2 [(M+H)+)] 435.24, found 435.20 (Figure 30). Capillary electropherogram
(Figure 57A).

2.5.6

Synthesis of 4ES and 5ES

To a solution of 1E (340 mg, 1.44 mmol, 1.0 equiv) in DMF (12 ml) were added cesium
carbonate (234 mg, 0.72 mmol, 0.5 equiv) and methyl iodide (0.45 ml, 7.20 mmol, 5.0
equiv) under N2. The reaction mixture was stirred for 15 hours, was quenched with 2N HCl
and extracted into EtOAc. The organic extract was dried using an. Na2SO4, evaporated and
the residue purified on silica gel (10-25% EtOAc in hexanes) to give 2E (192 mg, 0.77
mmol, 53%) and 3E (108 mg, 0.43 mmol, 30%). 2E; 1H NMR (CDCl3, 300 MHz) δ 1.46
(t, J=6Hz, 3H, CH3), 2.75 (s, 3H, CH3), 3.96 (s, 3H, CH3), 4.39 (q, J =6 Hz,, 2H, CH2),
5.58 (s, 1H, OH) 6.95 (s, 1H, Ar-H), 7.44 (s, 1H, Ar-H) (Figure 31) . ESI (+ve) m/z calcd
for C13H14O5 [(M+H)+)] 251.25, found 251.17; 3E; 1H NMR (CDCl3, 300 MHz) δ 1.42 (t,
J=6 Hz, 3H, CH3), 2.69 (s, 3H, CH3), 3.94 (s, 3H, CH3), 4.40 (q, J =9 Hz, 2H, CH2), 5.83
(s, 1H, OH), 7.00 (s, 1H, Ar-H), 7.40 (s, 1H, Ar-H) (Figure 32), NOESY for 2E (Figure
33).

To a solution of 2E (34 mg, 0.136 mmol, 1.0 equiv) in acetonitrile (0.45 ml) in a
microwave tube were added triethylamine (0.18 ml, 1.3 mmol, 10 equiv) and
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trimethylamine-sulfur trioxide complex (151.4 mg, 1.08 mmol, 8.0 equiv) under nitrogen.
The reaction mixture was exposed to microwaves (50 W, 30 min, 1000C). The mixture was
concentrated in vacuo and purified by flash chromatography on silica gel (0-20% MeOH in
DCM) and dried to give the triethylamine-sulfate salt. This was dissolved in 20% EtOHwater and loaded onto a Sephadex C-25 column. Appropriate fractions were pooled and
lyophilized to give 4ES (45 mg, 0.13 mmol, 94%). 1H NMR (DMSO d6, 300 MHz) δ 1.35
(t, J = 6 Hz, 3H, CH3), 2.52 (s, 3H, CH3), 3.78 (s, 3H, CH3), 4.32 (q, J = 6 Hz, 2H, CH2),
7.25 (s, 1H, Ar-H), 7.97 (s, 1H, Ar-H) (Figure 34).
To a solution of 3E (50 mg, 0.2 mmol, 1.0 equiv) in acetonitrile (0.7 ml) in a microwave
tube were added triethylamine (0.27 ml, 2.0 mmol, 10 equiv) and trimethylamine-sulfur
trioxide complex (222.6 mg, 1.6 mmol, 8.0 equiv) under nitrogen. The reaction mixture
was exposed to microwave energy (50 W, 30 min, 1000C). The mixture was concentrated
in vacuo and purified by flash chromatography on silica gel (0-20% MeOH in CH2Cl2) and
dried to give the triethylamine-sulfate salt. This was dissolved in 20% EtOH-water and
loaded onto a Sephadex C-25 column. Appropriate fractions were pooled and lyophilized
to give 5ES (65 mg, 0.18 mmol, 92%). 1H NMR (D2O, 300 MHz) δ 1.13 (t, J = 6 Hz, 3H,
CH3), 2.18 (s, 3H, CH3), 3.56 (s, 3H, CH3), 3.94 (q, J = 9 Hz, 2H, CH2), 6.63 (s, 1H, ArH), 7.13 (s, 1H, Ar-H) (Figure 35).
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NOESY for 2E with distinctive correlation’s in yellow
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2.5.7

Synthesis of 4AS and 5AS

4ES (45 mg, 0.123 mmol, 1.0 equiv) was dissolved in DMSO (1.3 ml). To this solution
were added potassium tert-butoxide (TCI AMERICA) (45.1 mg, 0.369 mmol, 3.0 equiv)
and H2O (3.3 ml, 0.184 mmol, 1.5 equiv) under nitrogen. The reaction was monitored on
reverse phase HPLC and after 3 hours dibasic sodium phosphate (174.6 mg, 1.23 mmol,
10.0 equiv) was added and stirred for an additional 30 minutes. The reaction mixture was
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions with
the product were identified using reverse phase HPLC and lyophilized to obtain 4AS (38.3
mg, 0.11 mmol, 90%). 1H NMR (D2O, 300 MHz) δ 2.45 (s, 3H, CH3), 3.73 (s, 3H, CH3),
7.04 (s, 1H, Ar-H), 7.61 (s, 1H, Ar-H) (Figure 36). 13C NMR 13.37, 56.44, 96.32, 113.81,
114.75, 120.20, 137.10, 149.21, 151.28, 160.18, 172.46 (Figure 37). ESI (+ve) m/z calcd
for

C11H8Na2O8S

[(M+H)+)]

346.97,

found

347.15

(Figure

38).

Capillary

electropherogram (Figure 57A)
5ES (73 mg, 0.199 mmol, 1.0 equiv) was dissolved in DMSO (2.0 ml). To this solution
were added potassium tert-butoxide (TCI AMERICA) (73 mg, 0.598 mmol, 3.0 equiv) and
H2O (5.3 μl, 0.298 mmol, 1.5 equiv) under nitrogen. The reaction was monitored on
reverse phase HPLC and after 3 hours dibasic sodium phosphate (282.5 mg, 1.99 mmol,
10.0 equiv) was added and stirred for an additional 30 minutes. The reaction mixture was
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions with
the product were identified using reverse phase HPLC and lyophilized to obtain 5AS (62
mg, 0.18 mmol, 90%). 1H NMR (D2O, 300 MHz) δ 2.50 (s, 3H, CH3), 3.78 (s, 3H, CH3),
7.32 (s, 1H, Ar-H), 7.39 (s, 1H, Ar-H) (Figure 39).
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13

C NMR 13.60, 56.67, 104.48,

105.74, 113.99, 125.63, 137.24, 146.75, 148.54, 161.61, 172.44 (Figure 40). ESI (+ve)
m/z calcd for C11H8Na2O8S [(M+H)+)] 346.97, found 347.15 (Figure 41). Capillary
electropherogram (Figure 57A)
2.5.8

Synthesis of 2A

To a solution of 2E (50 mg, 0.2 mmol, 1.0 equiv) in EtOH (2 ml) in a 2-necked flask fitted
with a condenser was added 2N NaOH (0.3 ml) and the mixture was heated to 800C. After
16 hours, the completion of the reaction indicated by TLC, the reaction mixture was cooled
to room temperature and quenched, acidified with 2N HCl and extracted with ethyl acetate.
The organic extract was dried (an. Na2SO4), concentrated in vacuo and purified using flash
chromatography on silica gel (50% EtOAc in hexanes) to give 2A (40 mg, 0.18 mmol,
90%). 1H NMR (CH3OD, 300 MHz) δ 2.66 (s, 3H, CH3), 3.88 (s, 3H, CH3), 7.05 (s, 1H,
Ar-H), 7.32 (s, 1H, Ar-H) (Figure 42).

13

C NMR 13.16, 55.51, 94.55, 106.08, 108.83,

119.12, 144.00, 146.66, 148.03, 162.37, 166.49 (Figure 43). ESI (-ve) m/z calcd for
C11H10O5 [(M-H)-)] 221.05, found 220.98 (Figure 44). Capillary electropherogram
(Figure 57B)
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2.5.9

Synthesis of 1X

To a solution of LiAlH4 (15.18 mg, 0.4 mmol, 5.0 equiv) in THF (0.8 ml) was added
compound 2E (20 mg, 0.08 mmol, 1.0 equiv) in THF (0.8 ml) drop wise, slowly under
nitrogen. The reaction mixture was stirred for ten hours after which 6 μl of H2O, 6 μl of 15
% w/v NaOH and 18 μl of H2O were added successively. Afterwards ethylacetate was
added to the mixture and was stirred for 30 minutes. The crude was filtered over celite and
dried (an. Na2SO4), concentrated in vacuo and purified on silica gel (0-40% EtOAc in
hexanes) to obtain 1X (14 mg, 0.067 mmol, 84%, ). 1H NMR (acetone-d6, 300 MHz) δ 2.35
(s, 3H, CH3), 3.88 (s, 3H, CH3), 4.65 (s, 2H, CH2), 7.02 (s, 1H, Ar-H), 7.05 (s, 1H, Ar-H)
(Figure 45). 13C NMR 10.87, 54.01, 55.52, 94.41, 103.66, 114.74, 121.31, 142.87, 145.14,
147.50, 150.36 (Figure 46).

2.5.10 Synthesis of 7E and 7ES
To a solution of 2E (910 mg, 3.63 mmol, 1.0 equiv) in DMF (30 ml) was added imidazole
(1.20 g, 18.15 mmol, 5.0 equiv) and TBDMSCl (3.2 g, 21.83 mmol, 6.0 equiv) and the
mixture was stirred. After 16 hours the reaction mixture was diluted with water, extracted
with diethyl ether and the organic extract was dried (an. Na2SO4), concentrated in vacuo
and purified by flash chromatography on silica gel (0-15% EtOAc in hexanes) to obtain the
silyl protected derivative (1.19 g, 3.26 mmol, 89%).
A two-necked flask was charged with a solution of lithium aluminum hydride (520 mg,
13.71 mmol, 5.0 equiv) in THF (27 ml). To this solution under an atmosphere of nitrogen
was added in a dropwise manner (over a period of 20 minutes) a solution of the silyl
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derivative (1.0 g, 2.74 mmol, 1.0 equiv) in THF (27 ml). The mixture was stirred for 16
hours. After the completion of the reaction H2O (0.52 ml), 15% w/v aqueous NaOH (0.52
ml) and H2O (1.56 ml) were sequentially added. Then, the reaction mixture was poured
into diethyl ether and stirred for 30 minutes. The organic extract was filtered through
celite, dried (an. Na2SO4), concentrated in vacuo and purified using flash chromatography
on silica gel (10-30% EtOAc in hexanes) to give 9 (710 mg, 2.2 mmol, 80%). 1H NMR
(CDCl3, 300 MHz) δ 0.14 (s, 6H, CH3), 1.01 (s, 9H, CH3), 2.41 (s, 3H, CH3), 3.82 (s, 3H,
CH3), 4.69 (s, 2H, CH2), 6.93 (s, 1H, Ar-H), 7.01 (s, 1H, Ar-H) (Figure 47).
To a solution of 9 (100 mg, 0.310 mmol, 1.0 equiv) in CH2Cl2 (3.1 ml) were added
TEMPO (9.68 mg, 0.062 mmol, 0.2 equiv), tetrabutyl ammonium chloride (17.23 mg,
0.062 mmol, 0.2 equiv), NaHCO3 solution (3.1 ml, 0.5 M) and N-chloro succinimide
(124.18 mg, 0.93 mmol, 3.0 equiv). The reaction mixture was allowed to stir for 4 hours
and after the completion of the reaction as indicated on TLC, the mixture was extracted
with CH2Cl2 and water. The organic layer was dried (an. Na2SO4), concentrated in vacuo
and purified using flash chromatography on silica gel (20% EtOAc in hexanes) to give 10
(80 mg, 0.25 mmol, 81%). 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H, CH3), 1.01 (s, 9H,
CH3), 2.71 (s, 3H, CH3), 3.84 (s, 3H, CH3), 6.95 (s, 1H, Ar-H), 7.54 (s, 1H, Ar-H), 10.15
(s, 1H, CH) (Figure 48).

A two necked flask fitted with a reflux condenser was charged with a solution of 10 (120
mg, 0.374 mmol, 1.0 equiv) in benzene (2.5 ml). To this was added (carbethoxymethylene)
triphenylphosphorane (196 mg, 0.562 mmol, 1.5 equiv) under an atmosphere of nitrogen.
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The mixture was refluxed for 3.5 hours. Afterwards the reaction was brought to room
temperature and was diluted with CH2Cl2. The mixture was concentrated in vacuo and
purified by flash chromatography on silica gel (10% EtOAc in hexanes) to obtain the trans
isomer (140 mg, 0.36 mmol, 96%). 1H NMR (CDCl3, 300 MHz) δ 0.16 (s, 6H, CH3), 1.03
(s, 9H, CH3), 1.36 (t, J = 6Hz, 3H, CH3), 2.53 (s, 3H, CH3), 3.84 (s, 3H, CH3), 4.30 (q, J
=9Hz, 2H, CH2), 6.36 (d, J =15Hz, 1H, CH), 6.95 (s, 1H, Ar-H), 7.18 (s, 1H, Ar-H), 7.77
(d, J =18Hz, 1H, CH) (Figure 49).

A solution of the trans isomer (230 mg, 0.588 mmol, 1.0 equiv) in ethanol (6 ml) was
hydrogenated in Parr shaker apparatus over 46 mg of 10% Pd/C at room temperature and at
an initial pressure of 35 psig over a period of 4 hours. The catalyst was removed by
filtration over celite and washed with ether and acetone. The solvents were concentrated
under vacuo to obtain 260 mg of the crude compound, which NMR indicated partial desilylation had occurred. Crude 12 was used for the next step without purification.
To a solution of the crude 12 (176 mg, 1.0 equiv) in THF (2.61 ml) was added tetrabutyl
ammonium fluoride in THF (1 M in THF, 1.79 ml, 4.0 equiv) and stirred for a period of 4
hours. Afterwards the reaction was quenched with saturated ammonium chloride solution
and extracted into EtOAc. The organic extract was concentrated in vacuo and purified
using flash chromatography on silica gel to obtain 7E (130 mg, 0.47 mmol). 1H NMR
(CDCl3, 300 MHz) δ 1.22 (t, J = 6Hz, 3H, CH3), 2.36 (s, 3H, CH3), 2.59 (t, J = 6Hz, 2H,
CH2), 2.87 (t, J = 9Hz, 2H, CH2), 3.91 (s, 3H, CH3), 4.12 (q, J = 6Hz, 2H, CH2), 5.49 (s,
1H, OH), 6.93 (s, 1H, Ar-H), 6.94 (s, 1H, Ar-H) (Figure 50).
103

To a solution of 7E (34 mg, 0.122 mmol, 1.0 equiv) in acetonitrile (0.42 ml) in a
microwave tube were added triethylamine (0.16 ml, 1.22 mmol, 10 equiv) and
trimethylamine-sulfur trioxide complex (136.0 mg, 0.977 mmol, 8.0 equiv) under nitrogen.
The reaction mixture was exposed to microwaves (50 W, 30 min, 1000C). The mixture was
concentrated in vacuo and purified by flash chromatography on silica gel (0-10% MeOH in
DCM) and dried to give the triethylamine-sulfate salt. This was dissolved in 20% EtOHwater and loaded onto a Sephadex C-25 column. Appropriate fractions were pooled and
lyophilized to give 7ES (18mg, 0.047 mmol, 39%). 1H NMR (D2O, 300 MHz) δ 1.18 (t, J =
6Hz, 3H, CH3), 2.34 (s, 3H, CH3), 2.62 (t, J = 9Hz, 2H, CH2), 2.87 (t, J = 9Hz, 2H, CH2),
3.85 (s, 3H, CH3), 4.08 (q, J = 9Hz, 2H, CH2), 7.06 (s, 1H, Ar-H), 7.50 (s, 1H, Ar-H)
(Figure 51).

2.5.11 Synthesis of 7AS
7ES (18 mg, 0.047 mmol, 1.0 equiv) was dissolved in DMSO (0.5 ml). To this solution
were added potassium tert-butoxide (TCI AMERICA) (15.93 mg, 0.142 mmol, 3.0 equiv)
and H2O (1.5 μl, 0.0705 mmol, 1.5 equiv) under nitrogen. The reaction was monitored on
reverse phase HPLC and after 3 hours dibasic sodium phosphate (66.72 mg, 0.47 mmol,
10.0 equiv) was added and stirred for an additional 30 minutes. The reaction mixture was
loaded onto a Sephadex G-10 column and eluted with deionized water. The fractions with
the product were identified using reverse phase HPLC, lyophilized to obtain 7AS (16 mg,
0.043 mmol, 91%). 1H NMR (D2O, 300 MHz) δ 2.12 (s, 3H, CH3), 2.22 (t, J = 6Hz, 2H,
CH2), 2.61 (t, J = 6Hz, 2H, CH2), 3.66 (s, 3H, CH3), 6.94 (s, 1H, Ar-H), 7.23 (s, 1H, Ar-H)
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(Figure 52). ESI (+ve) m/z calcd for C13H12Na2O8S [(M+H)+)] 375.00, found 375.17
(Figure 53). Capillary electropherogram (Figure 57A).

2.5.12 Synthesis of 7A
To a solution of 7E (27 mg, 0.097 mmol, 1.0 equiv) in EtOH (0.9 ml) in a 2-necked flask
fitted with a condenser was added sodium hydroxide (0.15 ml from 2N soln) and the
mixture was heated to 800C. After 6 hours, the completion of the reaction indicated by
TLC, the reaction mixture was cooled to room temperature and quenched, acidified with
2N HCl and extracted with ethyl acetate. The organic extract was dried (an. Na2SO4) and
concentrated in vacuo and purified using flash chromatography on silica gel (5% MeOH
in EtOAc) to give 7A (12 mg, 0.048 mmol, 50%). 1H NMR (CH3OD, 300 MHz) δ 2.32 (s,
3H, CH3), 2.55 (t, J = 6Hz, 2H, CH2), 2.85 (t, J = 6Hz, 2H, CH2), 3.86 (s, 3H, CH3), 6.85
(s, 1H, Ar-H), 6.98 (s, 1H, Ar-H) (Figure 54). 13C NMR 10.66, 19.10, 33.85, 55.59, 94.86,
103.29, 112.66, 121.69, 142.80, 145.83, 148.28, 150.00 (note: one carbon missing
probably because of an overlap) (Figure 55). ESI (-ve) m/z calcd for C13H14O5 [(M-H)-)]
249.08, found 249.00 (Figure 56). Capillary electropherogram (Figure 57B).
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Figure 57A

Capillary electropherogram’s for 4AS, 5AS, 6AS and 7AS

Figure 57B

Capillary electropherogram’s for 1A, 2A and 7A
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2.5.13

Direct Inhibition of factor Xa and thrombin (Work performed by Dr. Liang)

Direct inhibition of thrombin and factor Xa by the benzofuran derivatives was determined
using chromogenic substrate hydrolysis assays. The buffer used in these experiments was 20
mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1%
polyethylene glycol (PEG) 8000. In these assays, 3 to 134 μL of a stock solution of
benzofuran derivatives in DMSO was diluted with appropriate volume of the buffer in PEG
20,000-coated polystyrene cuvettes to give 0.4 to 4.3 mM inhibitor concentration in a final
incubation volume of 1000 μL. Then 5 μL of the stock enzyme solution was added to give 4.8
nM thrombin or 1.1 nM factor Xa, followed by 20 μL of 1 mM Spectrozyme TH or 100 μL of
4.1 mM S-2772. The residual enzyme activity was determined from the initial rate of increase
in absorbance at 405 nm. Control experiments with DMSO without the benzofuran derivative
were performed to assess the loss of enzyme activity. Relative residual proteinase activity (in
%) at each concentration of the benzofuran derivative was calculated as a ratio of the slopes
measured in the presence of the inhibitor to that in its absence.

2.5.14

Michaelis-Menten Kinetics of S-2772 Hydrolysis by Factor Xa in the Presence

of 5AS (Work performed by Dr. Liang)
The initial rate of S-2772 hydrolysis by 1.1 nM factor Xa was monitored from the linear
increase in absorbance at 405 nm. The initial rate was measured as a function of various
concentrations of substrate S-2772 (20.5–492.0 μM) in the presence of 2.6 mM 5AS in 20
mM Tris-HCl buffer, pH 7.4, containing 100 mM NaCl, 2.5 mM CaCl2, and 0.1% PEG8000
at 25 °C. The data were fitted by the Michaelis-Menten equation to determine KM and VMAX.
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CHAPTER 3 Virtual screening of the synthesized β-5 like Compounds

3.1

Rationale

Designing non-sugar heparin mimics that recognize targets like antithrombin, thrombin
and fXa is a major challenge. Non-sugar scaffolds bearing multiple sulfate and carboxylate
groups of high chain length, e.g., of the size of heparin, are difficult to model. Modeling
such scaffolds is fraught with problems of specificity because of the surface exposed,
shallow heparin-binding sites on proteins with high density of positively charged residues,
which induces recognition of practically any collection of negative charges in these
molecules. Our lab had earlier designed the dual filter strategy for ligand docking using
GOLD, which consists of an ―affinity‖ and ―specificity‖ filter. This strategy successfully
reproduced the binding geometry of a crystallized sequence–specific heparin
pentasaccharide to within 2.5 Å for antithrombin-heparin interaction143.
Results described in chapter 2 show that selected β-5 like molecules inhibit fXa. Moreover,
a slight preference for the benzofuran scaffold was observed for inhibition of fXa when
compared to thrombin.
We sought to explore if the GOLD-based protocol of ligand docking, which was developed
for antithrombin-heparin interaction would help in our case, i.e., for explaining the
observed inhibition profile of the synthesized β-5 like molecules against factor Xa.
120

Furthermore, kinetic studies showed that these molecules inhibit fXa by an allosteric
mechanism of action. Based on the structural domains present in fXa, the synthesized β-5
like molecules would bind to the exosite-II in fXa. Therefore, it was an important point to
elucidate how these molecules interact with the exosite-II in fXa, and which residues of the
exosite-II are involved in binding.

3.2

Coordinates for the synthesized β-5 like molecules

The seven synthesized molecules which were observed to inhibit fXa; 1A, 2A, 4AS, 5AS,
6AS and 7AS, were drawn in SYBYL. The atom type of sulfur and oxygen atoms in SO3
was modified to S.o2 and O.co2, and the atom type for oxygen and carbon in
carboxylates was modified to O.co2 and O.Co2 respectively. The bond type between these
atoms was modified to aromatic. Each of the compounds in the library was minimized
using the Tripos force field with Gasteiger-Hückel charges, a fixed dielectric constant of
80, and a nonbonded cutoff radius of 8 Å. Minimization was carried out for a maximum of
10000 iterations subject to a termination gradient of 0.05 kcal/(mol.A).

3.3

Protein coordinates

The exosite in fXa is a surface-exposed, shallow, solvent exposed surface lined by basic
residues. Therefore, to define the binding site on fXa in GOLD, wherein the genetic
algorithm (GA) can sample all possible conformations of the ligand, the cavity detection
algorithm in GOLD cannot be used. This is because the exosite-II is not a hydrophobic
cavity where a ligand can be docked. Therefore, the binding site must be defined using a
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ligand in the bound site which implies it is crystallized with the protein. However, no
crystal structure has been deposited in the PDB with a ligand crystallized on the exosite-II
of fXa.
Yet, seven of the basic residues present on the exosite-II in fXa are conserved in thrombin
also2. These residues are Arg93, Lys96, Arg125, Arg165, Lys169, Lys236 and Arg240.
Additionally, the crystal structure of thrombin in complex with heparin octasaccharide was
available144 (PDB code 1XMN). Thus, fXa98 (PDB code 1HCG) and thrombin were
aligned by homology. The seven basic residues in the exosite-II of thrombin were spatially
found to be similar in orientation in fXa (Figure 58).
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Figure 58

Thrombin and fXa aligned by homology. The seven basic exosite-II

residues in fXa are conserved in thrombin. The blue ribbon is fXa and the magenta is
thrombin.

`

The next step in defining the binding site in GOLD was to place the heparin
hexasaccharide crystallized with thrombin onto the same site of fXa. Thus, the coordinates
of the heparin hexasaccharide were extracted and placed on the aligned structure of fXa
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and the binding site in GOLD was defined as 16 Å from every atom in the hexasaccharide
(Figure 59). This definition of the binding site covers all important known heparin binding
residues in fXa.

Figure 59

The binding site defined on fXa in GOLD. The binding site is shown as a

solid surface colored by lipophillic potential. Green represents hydrophilic surface and red
shows hydrophobic surface.
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3.4

Docking of β-5 like synthesized molecules onto fXa

The docking of seven synthesized compound, onto fXa was done by GOLD 4.0. GOLD is
a soft docking method that allows a small degree of interpenetration, or van der waals
overlap of ligand and protein atoms. GOLD also optimizes the positions of hydrogen-bond
donating atoms on Ser, Thr, Tyr and Lys residues as part of the docking process 146. For
docking, the specificity screen developed in our lab was used. This involves screening of
all possible sequences using 300000 genetic algorithm (GA) iterations, which is
collectively termed as one GA run. This ensures sampling of the entire conformational
space available in the predefined binding site of fXa. Here, GOLD starts with a population
of 100 arbitrarily docked ligand orientations and evaluates them using the GA fitness
function, which assigns them a GOLD score and improves their fitness by an iterative
optimization procedure that is biased towards higher scores. The initial population is
selected at random; hence several such runs are required to consistently predict bound
conformations. 10 GA runs were used in this study with the GOLD score to evaluate the
fitness and 10 such runs are collectively termed as one docking experiment. Furthermore,
the GA was set to preterminate if the top two ranked solutions came within 2.5 A RMSD
and the top two ranked solutions are saved. The docking was driven using the GOLD
scoring function. The final analysis of the computed solutions was done using the modified
GOLD score, which was found to correlate well with antithrombin binding affinities for
pentasaccharide variants143.
Modified GOLD score = HBEXT + 1.375 × VDWEXT
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Where HBEXT and VDWEXT are the ―external‖ (nonbonded interactions between the ligand
and the receptor) hydrogen bonding and van der waals respectively.
The docking experiments were run in triplicate to ensure greater confidence in docked
geometries. The top two solutions resulting from these runs (from each experiment) were
considered for further analysis. Hence, a triplicate docking experiment would yield a
maximum of six solutions. The RMSD between the six computed solutions were compared
and convergence of these 3 independent experiments is observed if the RMSD matrix
displays a set of 6 solutions within 2.5 Å of each other, indicating a high affinityspecificity sequence. Specificity here suggests a preference for a defined binding
geometry; wherein a particular sequence among the entire set of compounds can recognize
the protein binding site in a single, well-defined binding mode. Hence, all the seven
compounds which displayed inhibitory potential were docked using the adapted docking
algorithm developed in our lab (Figure 60).
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Figure 60

Docking algorithm used for present study (adapted from Raghuraman

et.al; J. Med. Chem. 2006, 49, 3553-3562) .
START

Build and Minimize
compounds

Specificity Screen
300,000 GA iterations, three
runs per molecule

NO
RMSD ≤ 2.5A?

YES

High-Specificity Sequence(s)

END
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DISCARD

3.5

GOLD explains the observed inhibition profile of the monomers

Out of the seven compounds, which were docked in triplicate, five of them (2A, 4AS, 5AS,
6AS and 7AS) were found to exhibit high specificity, i.e., the RMSD matrix indicated that
RMSD difference between the computed docked poses of the experiments ran in triplicate
came within 2.5 Å. Inspection of the computed binding mode of these 5 compounds
revealed that two of these compounds (5AS and 6AS) bind in exactly the same manner
interacting with the same residues (Lys236, Arg125, Lys

230

, Gln178) that came within

hydrogen bonding distance (Figure 61A and 61B).

Figure 61A

The docked pose of 5AS on exosite-II of fXa. The red lines indicate

hydrogen bonds
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Figure 61B

Overlay of the docked poses of 5AS and 6AS

Interestingly, these two compounds, 5AS and 6AS, were found to inhibit fXa 86% and
75% respectively at 2.6 mM. Inspection of the docked pose of compound 4AS, which is a
regioisomer of 5AS, indicates that it adopts a totally different docked pose on the exosite-II
of fXa with interacting only with Arg125, Lys230 and Gln178. (Figure 62A)

Figure 62A

The docked pose of 4AS. The red lines indicate hydrogen bonds
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This likely explains why 4AS inhibits fXa much weaker (42% at 2.6 mM) when compared
to 5AS (86% at 2.6 mM) and 6AS (75% at 2.6 mM). 4AS cannot adopt the docked pose
assumed by 5AS and 6AS, because if 4AS is overlaid on 5AS and 6AS, the sulfate can
interact with Arg125, Lys230 and Gln178. However, the carboxylate on position-3 of 4AS
does not have any residue to interact with, so 4AS assumes a different docked pose that
5AS and 6AS (Figure 62B)

Figure 62B

Overlay of docked poses of 4AS, 5AS and 6AS

Going over of the docked pose of 2A indicates that it adopts a totally different
conformation on the protein. Only the carboxylate on the position-3 of the ring interacts
with the backbone nitrogen of Lys236 (Figure 63).
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Figure 63

Docked pose of 2A on fXa. Red lines indicate hydrogen bonds

The only interaction observed between 2A and fXa is just one hydrogen bond between the
carboxylate and Lys236. This explains the much weaker inhibition of fXa observed by 2A
(34% at 2.6 mM).
Compound 7AS adopts a quite interesting pose on fXa. The 5-O-SO3 is seen to interact
with Arg125, Gln178 and Lys230. Moreover, the extended carboxylate linker interacts with
the backbone nitrogen of Lys236 (Figure 64A).
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Figure 64A

Docked pose of 7AS. The red lines indicate hydrogen bonds

When this pose of 7AS is overlaid with the docked poses of 5AS and 6AS, interesting
observations can be made (Figure 64B).
7AS has a docked pose almost similar to 5AS and 6AS. The sulfate interacts with the same
residues as which 5AS and 6AS interact but, the carboxylate is poised on the other side and
because of the extended linker; it is able to interact with the backbone nitrogen of Lys236.
This difference in the docked pose explains the weaker inhibition exhibited by 7AS (39%
at 2.6 mM).
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Figure 64B

Overlay of docked poses of 7AS, 5AS and 6AS.

3.6 Discussion
The design of allosteric inhibitors of fXa is a challenging task because of the inadequate
information of the exact binding site to be targeted and due to lack of robust computational
methods to solve this problem. Overall, we have the idea that the exosite-II in fXa is lined
by arginines and lysines, but which factors generate specificity is an ongoing debate.
Screening of our synthesized β-5 like monomers against fXa, generates some information
about which residues in the exosite-II play a critical role in driving specificity in binding.
Looking for any specific compounds in the bioactive synthesized series, only 5 molecules
were found to bind specifically, which are 2A, 4AS, 5AS, 6AS and 7AS. Interestingly, the
most active compounds in the series, 4AS, 5AS and 6AS were found to exhibit higher
specificity and affinity. Observing the calculated docked poses of the most potent
molecules in this series, 5AS and 6AS drives some interesting conclusions. Both of these
compounds are seen to interact with residues Lys236, Arg125, Lys

230

and Gln178. The 5-

OSO3 group in compound 5AS is seen to interact with no residue in the protease. Having a
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common pharmacophore i.e. the 6-OSO3 and the 3-COO- among these compounds and
both being docked consistently on the exosite-II supports and explains the observed
inhibition profile of these compounds. Furthermore, the regioisomer of 5AS, which is 4AS
having a much weaker inhibitory potential was found to be interesting during the
biological evaluation of these compounds, as it was found to inhibit fXa much weaker than
what was observed for 5AS. The docked pose of 4AS, 5AS and 6AS supports the
biochemical study. In addition, it supports the preferential recognition hypothesis, as can
be seen that 4AS interacts with Arg125, Lys230 and Gln178. The absence of the common
pharmacophore in 4AS seen in 5AS and 6AS renders 4AS incapable of making any
interaction with Lys236. Moreover, the 3-COO- is not seen to interact with any residue in
the protease explaining its weaker inhibitory profile.
Compound 2A is seen to interact only with Lys236. This explains why 2A inhibits the
protease much weakly. Inspection of the docked pose of 7AS overlaid with 5AS and 6AS
is exciting. The 5-OSO3- interacts with Arg125, Lys

230

and Gln178. However, the

carboxylate with the extended linker cannot assume a conformation such that it interacts
with the side chain of Lys236. The carboxylate is observed to make contacts with the
backbone nitrogen of Lys236. This explains the weaker inhibitory profile observed for this
compound.
A careful examination of what residues in the exosite-II of fXa drive specificity show that
the most potent compounds in the series (5AS and 6AS) interact with Lys236, Arg125, Lys
230

and Gln178. Also, all the other compounds that were found to be specific in GOLD

screening are seen to interact with the same above mentioned residues, but not necessarily
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with all of them. Hence, a pharmacophore, which can interact with all the above mentioned
residues, should be designed for displaying allosteric inhibition towards fXa.
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CHAPTER 4 Summary and Significance
A large number of inhibitors have been designed to target either fXa or thrombin. Nearly
all of these compounds act as competitive inhibitors that target the active site of the
proteases. However, nature favors a strategy that involves targeting the exosites on these
coagulation proteases and inhibiting them. Examples being; heparin that binds to the
exosite-II of thrombin and fXa and other peptides extracted from blood sucking leeches,
which also target the exosite of these proteases. So, evolutionarily this seems like preferred
tactic wherein exosites were evolved on these proteases for the modulation of their
function.

But, small molecules that act as allosteric inhibitors of factor Xa and thrombin

are unknown and the molecules studied here are the first example of such allosteric
inhibitors.
The molecules synthesized here are based on the β-5 like scaffold of CDSO3 and sulfates
and carboxylates were introduced differentially on them to target the exosite-II of thrombin
and fXa. The inhibition profile of these compounds indicated a preference for the β-5 like
scaffold for fXa over thrombin. Docking of these compounds on the exosite-II of fXa
explained the relevance of the pharmacophore that was extracted from the inhibition
profile.
These compounds were found to display inhibition of thrombin and fXa in the millimolar
range, which is fairly high. However, this is not too unexpected as these compounds are
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fairly small and have suboptimal binding features. Michealis-Menten kinetics indicated an
allosteric mechanism of enzyme inhibition, which is similar to the lead CDSO3.
Considering that the exosite-II in fXa and thrombin is 15-20Å long, the inhibition profile
exhibited by these compounds is quite promising. Moreover, the lead CDSO3 consists of
5-13 monomeric units and possible involves multiple dihydrobenzofuran and
phenoxypropanoic acid units to generate the observed nanomolar affinity. The coupling of
the most potent compounds in this study 5AS and 6AS with phenoxypropanoic acid units,
which are found in CDSO3 would result in radically different molecules from the known
ligands with high affinity.
Furthermore, the design of allosteric inhibitors for fXa and thrombin is difficult due to the
inadequate information of the important residues critical for binding and the mode of
binding. This inadequacy is amplified with heparin mimics because of the highly surface
exposed interaction involving electrostatic interactions. Yet, the novel allosteric
mechanism of these small synthetic molecules affords the opportunity to discover new
molecules with possibly different pharmacological and toxicological profile. Thus, the
synthetic molecules designed on the basis of CDSO3 scaffold may result in potent
functional mimics of heparin.
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APPENDIX A
Abbreviations used: APC, activated protein C; AT, antithrombin; APTT, activated partial
thromboplastin time; CA, caffeic acid; CEMTPP, (carbethoxy) methylene triphenyl
phosphorane; CD, dehydropolymer of caffeic acid; CDSO3, sulfated dehydropolymer of
caffeic acid; DEFGH, antithrombin-binding heparin pentasaccharide sequence; DHP,
dehydrogenation polymer; DIBAL, diisobutylaluminum hydride; DMSO, dimethyl
sulfoxide; GOLD, genetic optimization for ligand docking; HIT, heparin induced
thrombocytopenia; HMWK, high molecular weight kininogen; HRP, horseradish
peroxidase; IC50, concentration of inhibitor that results in 50% inhibition; LAH, lithium
aluminum hydride; LMWH, low molecular weight heparin; MMTPP, methoxymethylene
triphenyl phosphorane; Mw, weight average molecular weights; PT, prothrombin time;
RCL, reactive center loop; RMSD, root mean squared deviation; TEMPO, 2,2,6,6Tetramethylpiperidine-1-oxyl; TFPI, tissue factor pathway inhibitor; UFH, unfractionated
heparin.
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